president's report 2008

Education with a global perspective

AL

BA

NY

CO

LL

EG

E O

F P

HA

RM

AC

Y A

ND

HE

ALT

H S

CIE

NC

ES

PR

ES

IDE

NT

’S R

EP

OR

T 2

00

8

CoverF 4/15/09 1:43 PM Page 2

M A N AG I N G E D I T O R

Christine Shields

E D I T O R

Gil Chorbajian

C O N T R I B U T I N G W R I T E R S

Gil ChorbajianJames J. GozzoMark McCartyChristine ShieldsWinifred Yu

C O N T R I B U T I N G P H O T O G R A P H E R S

Gil ChorbajianDon ElliottPatrick RathbunKris QuaChristine Shields

D E S I G N

Coppola Design


ACPHS 2008 // 1

To be truly educated,students should havea global perspective.

PRES IDENT ’S MESSAGE 2 // FACULTY H IGHL IGHTS 4 // STUDENT H IGHL IGHTS 20 // F INANCIALS 26 // SCHOLARLY ACT IV ITY 28

PrezRepVF 4/15/09 1:35 PM Page 1

In last year’s report, I wrote, “We enjoy a strong reputation as a pharmacy

college, but we aspire to something even greater — to be viewed as a truly

extraordinary institute of higher learning.”

As you will read in the following pages, the College made measurable

strides towards that goal in 2008. The research taking place across all

departments at ACPHS is advancing health care by helping address

several of the world’s most pressing health threats.


ACPHS 2008 // 3

Susan Ludeman, Ph.D., for example, has an

active grant from the National Cancer Institute

which is examining how genetic factors influ-

ence the efficacy of chemotherapeutic drugs.

Thomas Lodise, Pharm.D., has received four

separate grants to determine the best courses

of treatment for patients infected with MRSA, a

potentially deadly bacteria that has been

described by NIH as ’a serious public health

concern.’

The College’s Pharmaceutical Research

Institute, headed by Shaker Mousa, Ph.D.,

marked its fifth anniversary in 2008 by securing

the largest single grant in its history. PRI will

receive $1.37 million over five years to help

develop an antidote for anthrax as part of a

joint effort with three other institutions.

Carlos Feleder, M.D., Ph.D., received an NIH-

funded grant in 2008 to study the role of the

spleen in managing fever. On the other end of

the temperature spectrum, Alex Steiner,

Pharm.D., Ph.D., is working to understand how

hypothermia may play a key part in preserving

tissue in patients with severe sepsis.

Given the quality of the research taking place

at ACPHS and the global importance of those

subjects being studied, it is little surprise that

investigators from around the world are seeking

to collaborate with our institution. The College

is working with academic, pharmaceutical and

biotechnology institutes in nearly 20 countries,

including: Australia, China, Japan, Egypt, Saudi

Arabia, Turkey, Switzerland, Germany,

Argentina, Brazil and Australia.

One of the primary beneficiaries of the research

taking place here is our students. Regardless of

their academic focus, students at ACPHS are

encouraged to participate in research projects.

The opportunity to work closely with faculty

and contribute in a meaningful way to their

research is one not often afforded to undergrad-

uates, and more students at the College are tak-

ing advantage of these unique opportunities.

Jaclyn Hosmer is one such student. She is a

third year Pharm.D. student who is working

with Assistant Professor Luciana Lopes,

Pharm.D., Ph.D., in researching new treat-

ments for skin cancer. There is also Alex

Villanueva, a fourth year student in the B.S.

in pharmaceutical sciences program, who

received a prestigious “Gateway to Research”

scholarship from the American Foundation

for Pharmacy Education to study hypoten-

sion with his mentor, Dr. Feleder. Several

more examples of exemplary student

research can be found in this Report.

When one considers the impact of these and

other initiatives, it becomes clear how our

research programs are distinguishing the

College in the region, across the nation and

around the world. As importantly, these pro-

grams are providing our students with a

wider range of educational opportunities —

from laboratory research to patient care. The

result is graduates who have a better under-

standing of the full spectrum of health care

and a global perspective on how best to

apply their knowledge.

PRESIDENT ’S MESSAGE

James J. Gozzo, Ph.D.


Department of Pharmaceutical Sciences assis-

tant professors Carlos Feleder, M.D., Ph.D, and

Alex Steiner, Pharm.D., Ph.D. are looking at tem-

perature in a new light in two separate research

projects at ACPHS. Both are taking an alternative

look at the role of temperature in fighting infec-

tion. Dr. Feleder recently won a grant to study

the role of the spleen in fever, while Dr. Steiner is

studying hypothermia’s effect on sepsis.

Though many studies have been conducted on

the liver’s impact on fever, the spleen’s role

remains relatively unknown. Dr. Feleder hopes

to change that with a $231,000 research grant

from the National Institutes of Health (NIH).

According to his research, the spleen plays an

important role in managing fever by releasing a

chemical that caps fever, preventing body tem-

perature from reaching dangerous levels. The

goal of his grant is to identify the chemical or

’factor’ being produced by the spleen during

fever and study its mechanism of action.

“Most research in this area has focused on the

liver as the key to managing fever,” says Dr.

Feleder. “Our initial findings show that the

activity of cells in the liver during fever is, in

fact, influenced by chemicals produced in the

spleen. If we understand how the body sets

upper limits on temperature and learn to influ-

ence this process, we can allow the body to

enjoy the benefits of fever and minimize the

potential threats, thereby accelerating the

recovery process.”

In the 1970s and 1980s, a University of Michigan

Medical School researcher named Matthew

Kluger challenged long held beliefs about fever.

Medicine’s approach to fever was to lower

body temperature in the majority of cases.

However, by infecting desert lizards with bac-

terium, he proved fever could be beneficial. In a

terrarium with hot and cold temperatures, he

gave the animals the option of voluntarily rais-

ing their body temperatures and found that

those who chose to raise their temperatures

survived. Fever plays a critical role in fighting

infection because immune cells are more effec-

tive in killing invading bacteria at higher tem-

peratures.

Similar to Kluger’s view of fever, Dr. Steiner sees

potential in the power of hypothermia. During

severe infection (systemic inflammation or sep-

sis), 90 percent of patients develop fever, and

10 percent develop hypothermia. Clinicians

think of hypothermia as a “wrong” reaction and,

much of the time, their approach is to raise

body temperature. With severe sepsis the lead-

ing cause of death among patients in non-coro-

nary intensive care units, hypothermia might

actually save tissues by lowering metabolic

demands and increasing profusion, Dr. Steiner

says. Fever, during severe infection, can dam-

age tissues, and hypothermia could possibly be

the body’s “strategy of last resort.”

“Body temperature influences everything, every

chemical reaction in your body,” Dr. Steiner

explains. “We’re not talking about cooling

patients; we’re talking about not heating septic

patients who spontaneously become hypother-

mic. Inaction might be best.”

While doing postdoctoral research in Arizona,

Dr. Steiner noted that rats with severe sepsis

choose to stay in a cool environment where

they can develop hypothermia, an indication

that hypothermia might be a natural physiolog-

ical response. Recognizing a gap in hypother-

mia research, he decided to pursue it. His

research at ACPHS thus far indicates that sep-

tic rats allowed to develop hypothermia (by

being kept in a cool environment) suffer less

tissue injury than rats forced to develop fever

(by being kept in a warm environment). He is

now carrying out experiments to identify which

temperature-dependent processes are primarily

responsible for such protection. During fever

and hypothermia, Dr. Steiner measures tissue

energy in the liver and kidney for signs of injury.

Both Dr. Feleder and Dr. Steiner see room for

collaboration in the future, and they say often

talk to each other about their research. They

can hardly avoid this, as their offices are next to

each other in the Biosciences Research Building

at ACPHS. Aside from temperature, they have

something else in common—another of Dr.

Feleder’s research projects focuses on the

brain’s response to sepsis.

Body temperature influences every chemical reaction in our bodies. In separateresearch projects, Dr. Carlos Feleder and Dr. Alex Steiner are taking an alternativelook at the role of temperature in fighting infection.

Dr. Alex Steiner, with research assistant Cathy Krall,

measures tissue energy in the liver and kidney during

fever and hypothermia.

Running hot and cold Investigating temperature’s role in fighting infection


ACPHS 2008 // 5

Dr. Carlos Feleder is investigating the role of the spleen in managing fever.


A large part of Dr. Ludeman’s current research

relates to cancer. Before landing at ACPHS, she

held positions as an associate professor in the

Division of Medical Oncology, Department of

Medicine, at Duke University Medical Center

and assistant professor in the Division of

Experimental Therapeutics and Pharmacology,

Department of Oncology, at the Johns Hopkins

University Medical Institutions. Her opportuni-

ties through these institutions have led to some

exciting research collaborations; she currently

has two active grants totaling $434,296.

One, through the National Cancer Institute,

involves the chemistry and pharmacology of

cyclophosphamide and related alkylating

agents, anticancer drugs which act by modify-

ing DNA. Many chemotherapeutics target DNA

in cancer cells so as to disrupt cell function and

cause cell death, explains Dr. Ludeman. But the

body’s natural defense mechanisms include

repair “machinery” that will attempt to fix the

damage to DNA.

“If we can pinpoint this repair sequence, we

may be able to stop it,” Dr. Ludeman says, thus

increasing the efficacy of chemotherapy.

The study also includes a pharmacogenetic

component. Cyclophosphamide and related

alkylating agents must be activated in the liver

to be effective, but, depending on hepatic

enzyme activity, these drugs are subject to

competing reactions. The alternative pathways

lead to toxic side effects that can significantly

decrease the drugs’ effectiveness.

“A genetic factor may predetermine if the

drugs will work,” says Dr. Ludeman. “With most

chemotherapy, weeks or months are required

before you see the effects.” By knowing ahead

of time if a drug has a chance of being effec-

tive, oncologists might be able to avoid wasting

precious treatment time as well as undesirable

side effects.

Another grant, from the National Institute on

Aging, in collaboration with North Carolina

State University, involves antioxidant metabo-

lism in the brain. Research suggests that the

loss of antioxidants, especially glutathione, may

speed the aging process and the onset of dis-

eases such as Parkinson’s and Alzheimer’s.

Although scientists have tried to increase levels

of glutathione to slow the effects of aging, oral

doses have been ineffective.

Glutathione is naturally synthesized in the brain

from three amino acids. Dr. Ludeman’s role is to

synthesize molecules related to these “building

blocks,” or prodrugs, which are more readily

transported across the blood brain barrier. The

prodrugs contain a “label” which can be visual-

ized through MRI techniques. Working with

rats, the team uses brain imaging to non-inva-

sively follow the uptake and conversion of

these prodrugs to glutathione.

Over the years, Dr. Ludeman has worked close-

ly with researchers with many different areas of

expertise and from all over the world to come

up with some innovative treatments, several of

which she holds patents on.

One project at Johns Hopkins resulted in

Gliadel™, a clinically used drug delivery system

for brain cancer. Gliadel is a dime-sized wafer

composed of a polymer which slowly releases

an anticancer agent. Multiple wafers are

implanted in the cavity left after a surgeon

removes as much of a brain tumor as possible;

the purpose of the implant is to release drug

directly at the site of any remaining cancer

cells. The project was a multi-disciplinary effort

involving neurosurgeons, oncologists, chemical

engineers, polymer chemists, organic chemists,

pharmacologists, biologists and representatives

from the pharmaceutical industry.

“Working in a medical center you get to see the

impact of your projects and how important col-

laborations between different disciplines are,”

says Dr. Ludeman.

Another patent derived from chemistry, cell

biology and pharmacology is for a dye that

detects certain types of stem cells by causing

them to light up under spectroscopy. Once iso-

lated from, for example, marrow or cord blood,

these stem cells can be injected into the patient

in the hopes of a therapeutic response such as

tissue regeneration or a treatment for leukemia.

The dye is commercially available for research

purposes and cells isolated using this dye are

being tested as part of regenerative tissue ther-

apies in clinical trials at medical centers around

the United States.

Susan Ludeman, an associate professor of organic chemistry in the Department of Arts and Sciences, is working across disciplines to delve into the mechanisms of diseases such as cancer andAlzheimer’s and develop novel approaches to their treatment.

The Right ChemistryCutting Edge Research Crosses Disciplines


ACPHS 2008 // 7

“It is performing well in a major clinical trial with

people who are in danger of losing their limbs,”

explains Dr. Ludeman.

After spending the fall semester setting up her

new lab, Dr. Ludeman is ready to get students

involved in her research and has three, includ-

ing one freshman, signed on for the spring.

“The interdisciplinary nature of Dr. Ludeman’s

work provides students an excellent opportuni-

ty to participate in cutting-edge research that

spans the fields of chemistry, biochemistry and

pharmacology,” says David Clarke, Ph.D., Arts

and Sciences department chair.

“My own undergraduate research experience

ignited my excitement for chemistry and

became the springboard for my decision to

enter graduate school and pursue an academic

career,” Dr. Ludeman says. “I am a huge propo-

nent of undergraduates being given the oppor-

tunity to discover their own interests and paths.

It’s exciting to see students make something

that has never been made before.”

Dr. Ludeman holds a patent on an assay for detecting certain types

of stem cells. The assay is known commercially as Aldefluor™ and

its key component is a dye known as BODIPY aminoacetaldehyde.

This dye, which was designed by Dr. Ludeman, is shown as an

energy-minimized, van der Waals surface model (ChemDraw 3D).

Dr. Ludeman demonstrates a rotary evaporator

to Mike D’Alessandro, a second-year student in

the Pharmaceutical Sciences program.

Susan Ludeman’s research involves the chemistry and pharmacology

of cyclophosphamide (known clinically as Cytoxan™) and related

alkyating agents. Shown is an energy-minimized, van der Waals

surface structure of cyclophosphamide (ChemDraw 3D).


ACPHS 2008 // 9

With students now in all four years of the pro-

gram and every course in all three tracks

offered for the first time, several new part-time

faculty members were added to the depart-

ment during the year, joining associate profes-

sors Indra Balachandran, Ph.D., and Elyse

Wheeler, Ph.D.; Assistant Professor Victoria

Peters, M.S. Ed.; and Instructor Joe Walker, B.S.

In addition, Lawrence Lansing, M.D., has joined

the department in a full-time capacity. A Board

Certified Pathologist and active researcher, Dr.

Lansing brings a unique clinical insight to the

classroom.

More courses were added as well. The CLS pro-

gram alone implemented 11 new courses and

associated labs in 2008 including classes in

advanced hematology, immunohematology and

molecular techniques.

Both the cytotechnology and the clinical lab-

oratory sciences tracks have graduated their

first bachelor’s degree students while five stu-

dents received post-baccalaureate Certificates

in Cytotechnology. All of the graduates passed

the American Society of Clinical Pathology

Registry exam required to work as cytotech-

nologists and are employed in hospitals and

private labs.

The University of Rochester Medical Center,

New York Presbyterian Hospital and Long Island

Jewish Medical Center were added as new clini-

cal affiliations, providing additional opportunities

for students in the cytotechnology program.

Currently, there are more than 20 clinical affili-

ates in hospitals and private laboratories in the

Capital District and across the country.

The program has grown not only in size, but

also has acquired some crucial new equip-

ment. Since moving to the cytotechnology

classroom at the College’s facility at 84

Holland Ave., the student experience has been

enhanced by the addition of a ThinPrep T2000

processor made possible with a grant from the

Bender Family Foundation and the help of

Hologic. ThinPrep is one of two FDA-approved

methods for making liquid-based preparations

of specimens in a cytology lab. With the new

processor, the program can increase teaching

cases of ThinPrep material and offer hands-on

experience to students.

In addition, the program has received support

from BD Tripath to increase SurePath cases,

another method of making liquid-based gyneco-

logic, non-gynecologic and fine needle aspirations.

A multi-headed review scope received from

Albany Medical Center helps faculty to demon-

strate the criteria for diagnosis of infections,

pre-malignant changes and malignancies simul-

taneously to nine students. It is also used

extensively for reviewing students’ unknown

cases.

“In this format, each student learns from,

not only his or her unknown cases, but also

from those of their classmates,” says Dr.

Balachandran, director of the cytotechnology

program. “This, in turn, increases the students’

confidence in criteria and diagnosis of disease

processes.”

The CLS program has made progress this year

as well, completing its self-study, a major step

toward receiving accreditation by the National

Accrediting Agency for Clinical Laboratory

Science (NAACLS).

The Department of Health Sciences at ACPHS expanded in many exciting directions in 2008. Thedepartment made significant progress toward the complete implementation of the three tracks withinthe B.S. in Biomedical Technology program: Clinical Laboratory Science (CLS), Cytotechnology andPhysician Assistant Studies, further enhancing the range of academic programs now offered at the College.

Putting the Health Sciences into ACPHSGrowing Enrollment, Expanded Programs


“The Clinical Laboratory Science program has

achieved ’Serious Applicant’ status through the

NAACLS, which allows our students to sit for

certifying and licensing exams,” says program

director Vickie Peters. “Full accreditation is

expected by May of 2009.”

The program is also finalizing affiliation agree-

ments with Hudson Valley and Schenectady

Community Colleges.

ACPHS also offers a unique program with

Albany Medical College’s (AMC) Center for

Physician Assistant Studies. The joint program

begins at ACPHS with academic preparation

and training in basic science and a clinical labo-

ratory specialty. Upon completion, in January of

their senior year, students enter a two-year M.S.

program in Physician Assistant Studies at the

Medical College. The program offers an excel-

lent pathway for students seeking to “lock in”

one of the coveted spots in AMC’s highly com-

petitive physician assistant program.

The department promises to grow even more

during the 2008–2009 academic year. Hassan

El-Fawal, Ph.D., has joined the College as the

new chair of Health Sciences. Dr. El-Fawal

received his B.Sc. in Entomology and Pesticide

Chemistry from the University of Alexandria,

Egypt, M.Sc. in Biomedical Sciences from

University of Guelph, Canada, Ph.D. in

Biomedical and Environmental Sciences

from Virginia Polytechnic Institute and State

University and postdoctoral fellowship at the

USEPA in Research Triangle Park, N.C. A spe-

cialist in the area of toxicology, he previously

worked at Mercy College School of Health

Clinical Laboratory Sciences Director

Vickie Peters spends a great deal

of time in the lab with students.


ACPHS 2008 // 11

Professions and Natural Sciences and New York

University School of Medicine. His full-time

appointment as professor and chair of Health

Sciences took effect in January. He also holds

a joint appointment in the Department of

Pharmaceutical Sciences.

With more than 20 years of academic and

research experience, Dr. El-Fawal does not hesi-

tate to cross lines between the humanities and

the basic and applied sciences. He has devel-

oped and taught biomedical curricula for such

diverse programs as Physical and Occupational

Therapy, Communication Disorders, Physician

Assistant Studies, Acupuncture and Oriental

Medicine, Nursing and Clinical Laboratory

Sciences. In addition he has mentored students

in Neuroscience, Pharmacology and

Environmental Medicine.

Dr. El-Fawal was attracted to ACPHS because

of its “entrepreneurial spirit and mission to pro-

vide a quality education in an environment hos-

pitable to students and researchers, alike.” He is

particularly impressed by the College’s accom-

plishments and growth, both physically and

intellectually, in the past decade though efforts

such as PRI, graduate degree offerings and the

ability to attract cutting-edge researchers.

“The College is poised to write a new chapter in

biomedical advancement and education.” He

sees himself a part of that vision.

“We are defining Health Sciences in the broad-

est sense, establishing a foundation that is

inclusive of such cutting-edge growth fields

as biotechnology, molecular diagnostics,

immunotechnology and environmental health,

as well as being at forefront of clinical diagnos-

tics,” says Dr. El-Fawal. “The cornerstone of this

foundation is to be student-centered and build

an intellectual partnership between faculty,

students and the institution. ACPHS has the

intellectual capital, the will and the energy to

be a pioneer in biomedical education.”

A ten-headed microscope allows Joe Walker, education coordinator

for cytotechnology, and students to simultaneously review cases.


Across the globe, pharmaceutical researchers, instructors and students are getting a glimpse of the workbeing done at Albany College of Pharmacy and Health Sciences. At the same time, they’re sharing theirknowledge with ACPHS students, faculty and researchers. The surge in international exchanges aroundthe world bodes well for the future of medicine and the treatment of major illnesses.

Going Global


ACPHS 2008 // 13

Doing pharmaceutical research with scientists

from other countries has numerous benefits,

says Shaker Mousa, Ph.D., executive vice presi-

dent and chairman of the Pharmaceutical

Research Institute at ACPHS. Under Dr. Mousa’s

direction, the Institute has obtained dozens of

research grants and equipment donations total-

ing more than $13 million since its establish-

ment in 2002. Now located in a spacious facili-

ty in Rensselaer, N.Y., PRI has grown from three

employees to 48 over the past five years, with

international experts in fields such as nanotech-

nology, medicinal chemistry, molecular biology,

cell biology and drug delivery and development

on staff.

“Our research collaborations bring international

recognition to the College and will draw gradu-

ate students to ACPHS from all over the world,”

says Dr. Mousa, a native of Egypt and the

founding director of PRI. “They make people

aware of our educational and research capabili-

ties while attracting scientists who bring new

dimensions to our work.”

Collaborations help pharmaceutical researchers

fulfill their ultimate goal: the advancement of

science. “The goal at the end of the day is to

save human lives,” Dr. Mousa says. “Science has

no boundaries, particularly when it comes to

benefiting mankind . Diversity and partnerships

are our greatest chance for success.”

Over the past five years, Dr. Mousa has devel-

oped national and international collaborations

with academic, pharmaceutical and biotechnol-

ogy institutes in the U.S., Japan, South Korea,

Saudi Arabia, Kuwait, the United Arab Emirates,

Egypt, Germany, France, England, Turkey,

Denmark, Australia, India and others.

THE MIDDLE EASTOne of the many collaborations now underway

involves work with researchers in the Middle

East on new approaches for treating breast

cancer. Breast cancer kills millions of women

around the world each year and affects millions

more. In the course of treatment, some women

become resistant to chemotherapy. Others

become very ill from the systemic effects of

anti-cancer drugs.

“We are trying to overcome the resistance

problem, so that the chemo can still be effec-

tive,” Dr. Mousa explains. “We’re also using nan-

otechnology to deliver chemo directly to the

cancer cells, so we can eliminate the horrible

side effects that result from the destruction of

healthy cells.”

Dr. Murat Yalcin from Uludag University in Turkey, shown here with ACPHS students

Evan Kujawski and Rebecca Reynolds, has assisted PRI with breast cancer research.


That’s where Olfat Shaker, M.D., came in. Dr.

Shaker, a professor of medical biochemistry

and molecular biology at Cairo University in

Egypt, was a visiting scholar at PRI in 2008.

Researchers at PRI provided technical support

and advice on nanoparticle formulations, while

Dr. Shaker offered data on tumor growth,

tumor angiogenesis and the impact of anti-

tumor agents on body organs. Their collabora-

tion will produce agents that will be tested on

animals, with the hopes of advancing to human

trials one day. The technology will also be

applied to liver cancer.

“We are starting to publish our joint works,” Dr.

Mousa says. “The next step is for us to go to

Egypt, where the incidence of liver cancer is

very high, to examine novel targets in liver can-

cer models and learn about the research taking

place there.”

Dr. Mousa also has the help of another overseas

researcher in a separate breast cancer project,

funded by a $406,400 grant from the United

States Department of Defense. Murat Yalcin,

Ph.D., a veterinarian researcher from Uludag

University in Bursa, Turkey, is here to assist

with research into non-anticoagulant heparin

(NACH) compounds and the delivery of

chemotherapy into breast cancer cells with

minimal impact on normal cells. During treat-

ment, these compounds may reduce the risk of

blood clotting, which is one of the most signifi-

cant and deadly side effects of chemotherapy.

PRI is also exploring the use of low molecular

weight heparin (LMWH) derivatives in the

treatment of renal cancer with researchers at

several universities in Dubai and Kuwait, where

the disease is more common than here in the

U.S. “There is direct evidence that these drugs

have an anti-cancer effect and that the anti-

Dr. Olfat Shaker, left, a professor of medical biochemistry and molecular biology from Cairo University in Egypt, shown

here with ACPHS student Anhtung Duong, visited PRI to share expertise in the areas of tumor growth and angiogenesis.

Panorama of a slide

showing breast adenocarcinoma,

viewed under a microscope.

A jumbled mass of cancer

forces its way in healthy

liver tissue in this

microscopic view.


ACPHS 2008 // 15

clotting effect is a secondary benefit,” Dr.

Mousa says.

The Institute’s work with LMWH derivatives

includes treating pain in patients with sickle cell

disease, an inherited blood disorder that causes

abnormal hemoglobin and disrupts blood flow.

Sickle cell disease affects as many as 3 in 10

people in Saudi Arabia as well as about 50,000

people in the U.S., most of them African-

American.

Findings from that research—which was

dubbed a “landmark study” by the American

Hematological Society—helped create guide-

lines for managing pain in sickle cell patients.

“We’re now doing a follow-up trial that will

show how to give home treatments for the

painful crisis,” Dr. Mousa says. “Now, instead of

going to the hospital to get an injection, we’re

coming up with a formula that patients can

self-administer at home.”

The sickle cell studies and other studies in the

United Arab Emirates have spawned the prom-

ise of another type of collaboration—providing

ACPHS faculty with the chance to teach contin-

uing education classes and workshops to phar-

macy graduates in Dubai. “It would a great

opportunity for our faculty,” Mousa says. “It

would be major exposure for the College, and

we would be teaching graduates from all over

the world.”

WORKING IN THE WESTThe Middle East is only one region of the world

working with PRI researchers. The institute is

also collaborating with scientists at the

University of Frankfurt in Germany. According

to Dr. Mousa, German scientists are very

advanced in embryonic stem cell research,

which may someday be used to treat vascular

diseases and thrombosis, repair tissue damage

caused by spinal cord injuries and trauma and

possibly even cure diabetes and other autoim-

mune diseases.

Dr. Mousa says he hopes to combine nanotech-

nology with non-embryonic stem cell research

to create a delivery system that will implant the

stem cells with the least amount of side effects.

Stem cells will then help regenerate tissue that

will help repair damaged tissue including

nerves, blood vessels and bones. “We could

potentially repair the heart in people with heart

failure,” he adds.

That same enthusiasm is being directed at

another project that seeks to reverse vision loss

in people with diabetes and macular degenera-

tion. Joining PRI researchers in that endeavor is

Evgeny Dyskin, M.D., who earned his Ph.D. from

the Medical Radiological Research Centre in

Obninsk, one of Russia’s leading scientific cen-

ters. Dr. Dyskin is continuing his ophthalmology

research at PRI and testing novel anti-angio-

genesis targets that prevent and reverse vision

loss in patients with diabetic retinopathy and

macular degeneration.

The project has also received the assistance of

ophthalmology and biotechnology researchers

from Showa University in Tokyo, Japan, who

spent three months at PRI.

Closer to home, PRI is part of a joint project

with the University of Toronto, Rensselaer

Polytechnic Institute and Biophage Pharma Inc.,

a Canadian company, to develop an antidote

for anthrax, a potentially deadly disease caused

by the naturally occurring Bacillus anthracis

bacterium. The group recently received a five-

year $6.2 million grant for the project, of which

PRI will receive $1.37 million.

The PRI research team will focus on optimizing

the concentrations of ’ingredients’ in the anti-

dote and look for ways to extend the product’s

shelf life. Though anthrax sometimes can be

treated with antibiotics, some forms of the dis-

ease are resistant to any form of therapy. An

antidote would provide an additional form of

treatment, one that might be more effective in

the latter stages of the disease when standard

treatments are less effective.

Anthrax bacteria are rod-shaped and highly pathogenic. Two forms

of the disease occur: in the lungs and on the skin. The skin infection

is usually treatable with antibiotics. Inhalation of anthrax spores and

the development of pulmonary anthrax is often fatal unless antibiotics

can be administered before the symptoms appear.

Stem cells can differentiate into any other cell type. There are three

main types of mammalian stem cell: embryonic stem cells, derived

from blastocysts; adult stem cells, which are found in some adult

tissues; and cord blood stem cells, which are found in the umbilical cord.


WORLD-WISE RESEARCH AND LEARNINGInternational research is happening in the labo-

ratories on campus, as well; a reflection of the

pharmaceutical industry’s efforts to do more

global research and the College’s drive to pro-

vide students a more worldly education.

Carlos Feleder, M.D., Ph.D., an assistant profes-

sor in the Department of Pharmaceutical

Sciences, has been working with Xiujuan Yao, a

Ph.D. candidate from the China Pharmaceutical

University in Nanjing. Yao is at ACPHS for two

years on a fellowship to supervise research

activities related to a grant Dr. Feleder received

from the National Institutes of Health to study

the role of the spleen in managing fever (see

page 8).

In addition, Dr. Feleder is working with Rodolfo

Cutrera, Ph.D., a professor in the Department of

Physiology at the University of Buenos Aires in

Argentina. Their research is looking at how the

central nervous system mediates the initiation

of septic shock and how prenatal immune chal-

lenges, such as stress and infections, affect

behavior during adulthood. Their work has

been published in several journals.

Dr. Feleder is also working with M. Sertac

Yilmaz, M.D., Ph.D., a visiting scientist from

Uludag University School of Medicine in Bursa,

Turkey. Together with William Millington, Ph.D.,

chair of the Department of Pharmaceutical

Sciences, they are studying and publishing arti-

cles on the role of the brain in septic and hem-

orrhagic shock. Along with another scientist

from Uludag University, they are planning a

symposium on the topic at a scientific meeting

in Antalya, Turkey, in November 2009.

Separately, Dr. Millington has been working

with Sinan Cavun M.D., Ph.D., and Gokhan

Goktalay, M.D., Ph.D., associate professors of

pharmacology at Uludag. The trio is studying

a brain chemical called glycyl-glutamine

(Gly-Gln) and its role in the prevention of

addiction to drugs such as nicotine and mor-

phine. Their research on rats has shown that

Gly-Gln reduces the effects of morphine and

nicotine and the severity of withdrawal from

these drugs.

Dr. Cavun has taken the research even further

in Uludag, using microdialysis techniques not

available at ACPHS. “He showed that Gly-Gln

inhibits the euphoria that a morphine high

produces by preventing the morphine-induced

release of dopamine in the brain reward path-

way,” Dr. Millington says. Meanwhile, Dr.

Goktalay is in Ankara, Turkey, testing whether

Gly-Gln is effective in animal models of anxiety

and epilepsy.

Another faculty member working with interna-

tional researchers is Robert M. Levin, Ph.D., pro-

fessor of pharmaceutical sciences. Most of Dr.

Levin’s research is in lower urinary tract func-

tion and dysfunction in both males and

females. He has worked with several scientists

from Maruzen Pharmaceuticals of Hiroshima,

Japan to study the use of kohki tea for the

treatment of urinary bladder dysfunction due

to an enlarged prostate. Kohki is a leaf rich in

antioxidants that comes from a plant in China,

and is formulated into a medicinal tea by

Maruzen.

Dr. Levin also works with other international

researchers from Taiwan, Korea and China on

studies involving lower urinary tract dysfunc-

tions including incontinence and interstitial cys-

titis in women.

Still to come is a new venture between Luciana

Lopes, PhD., an assistant professor of pharma-

ceutical sciences at ACPHS, and Maria Vitoria

Bentley, Ph,D. of the Pharmacy School of

Ribeirao Preto at the University of Sao Paulo

in Brazil. The two researchers will study the

development and characterization of new

transdermal delivery systems. Jaclyn Hosmer,

a Pharm.D. student at ACPHS, is also involved

in the research (see story page 20).

Dr. William Millington is working with scientists

from Turkey on the role of the brain chemical

glycyl-glutamine in preventing drug addiction.

Ophthalmology and biotechnology researchers from Showa University in Tokyo,

shown here with Dr. Shaker Mousa and ACPHS President James J. Gozzo,

spent three months at PRI on cutting-edge research to reverse vision loss in

people with diabetes and macular degeneration.


ACPHS 2008 // 17

MORE STUDENTS ABROAD At the same time, more and more ACPHS

students are studying at foreign universities.

ACPHS already has programs with the

University of Basel in Switzerland and Maruzen

Pharmaceuticals and is working on developing

more.

In Basel, for example, sixth-year Pharm. D. stu-

dents engage in clinical testing at the University

Hospital and gain experience working in Swiss

hospitals and retail pharmacies. They also

spend time at a heroin clinic, visit corporations

like Roche and Novartis and complete research

projects that, in some cases, result in publica-

tions, says Kevin Hickey, Ph.D., an assistant pro-

fessor in the Department of Arts and Sciences,

who has overseen the program since 2004. In

exchange, Dr. Hickey invites students from

Basel to do research with ACPHS faculty. “The

hope is that this partnership will grow into not

only more student exchanges, but also faculty

collaborations and exchanges and innovative

teaching technologies such as sharing lectures

via video-streaming,” he says.

Over in Hiroshima, Japan, students have the

chance to do research at Maruzen

Pharmaceuticals, a company specializing in

natural products. Since 2001, Dudley Moon,

Ph.D., professor of biological sciences, has

coordinated a five-week internship for ACPHS

students at Maruzen R&D Centers. The experi-

ence, which also meets the requirements for a

Pharm.D. rotation, kicks off with study of the

Japanese language.

Anna Leung, 23, of New York City, had the

opportunity to go to Maruzen in the summer of

2008. While there, she did research on natural

products. “We extracted, purified and tested

chemicals from plants,” she said. “After work

hours, the staff was kind enough to show us

around. There were also many cultural events

organized to help us experience Japan.”

Even with these well-established programs, the

College continues to forge new ties and, in

coming months, will offer students the chance

to study at the University School of Pharmacy

in Yeditepee, Turkey, and Uludag University

School of Medicine in Bursa, Turkey. The college

is also on the brink of establishing exchanges

with the National University of La Plata, School

of Pharmacy, in Argentina; the University of

Belgrano, School of Pharmacy, in Buenos Aires,

Argentina and the University of Santiago de

Compostela, School of Pharmacy, in Spain.

“We are developing joint training programs for

both undergraduate and graduate students,

whereby we will exchange students and facul-

ty,” Dr. Feleder says. “We will also apply for a

grant for the project from the European Union,

which provides support for these kinds of inter-

actions between universities.”

For his part, Andy Zheng, Ph.D., an assistant

professor of pharmaceutical sciences, is trying

to build ties to Fudan University in Shanghai

and hoping to create education and research

opportunities for graduate students and rota-

tions for Pharm.D. students. “We want to try

and send graduate students to China to study

traditional Chinese and herbal medicine,” he

says.

Meanwhile, in the Department of Arts and

Sciences, Assistant Professor Ray

Chandrasekara, Ph.D., is working to establish

research and rotation opportunities for ACPHS

students in Southeast Asia, most notably

Cambodia and Vietnam, especially for students

interested in going on to medical school.

“These experiences are eye opening and would

set them apart from other students,” Dr.

Millington says.

Working with international scientists creates

other possibilities too. Last June, the connec-

tion with Maruzen gave rise to the first-ever

Nature-ceuticals Symposium at ACPHS.

According to Dr. Moon, chair of the event’s

organizing committee, the conference exposed

faculty and students to natural products, which

have long been an important part of Japanese

culture and are becoming increasingly popular

among U.S. consumers. Highlights of the event

included a keynote address by David M.

Eisenberg, director of the Division of Research

and Education in Complementary Medicine at

Harvard Medical School and a Japanese tea

ceremony. Dr. Moon hopes to stage another

conference in 2011.

“To be truly educated, students should have a

global perspective,” says Dr. Millington.

Based on the number of collaborations in place

and under development, an increasing number

of students at ACPHS are now gaining that

global perspective—both scientifically and

culturally. The result is graduates who leave

the campus with a greater sense of themselves

and the world around them.

A Japanese tea ceremony was one of the

highpoints of the Nature-ceuticals Symposium

held at ACPHS in June 2008.

Extracts of tea leaves have been used medicinally in East Asia for

hundreds of years. Dr. Robert Levin has worked with scientists in

Japan to study their use to treat bladder dysfunction.


Dr. Lodise, an associate professor in the

Department of Pharmacy Practice at ACPHS,

has received four grants totaling $469,598 to

study methicillin-resistant staphylococcus

aureus (MRSA) and the various antibiotics used

to treat infections from this potentially deadly

bacteria.

“The dramatic increase in MRSA infections—

in both health care and community settings—

is a cause for great concern for health care

practitioners,” says Dr. Lodise. “One of the goals

of this research is to determine the best course

of treatment for patients infected with MRSA.”

MRSA is a type of staph infection that is

demonstrating increased resistance to the

medications typically prescribed to treat it.

According to the National Institutes of Health

(NIH), “MRSA has evolved from a controllable

nuisance into a serious public health concern.”

MRSA can present in two forms. The first,

Health Care Associated MRSA, is common in

settings such as hospitals and nursing homes

and among people with weakened immune

systems. Community Associated MRSA, which

infects otherwise healthy people, is usually

found in settings where there is close contact

among people, such as schools. The death rate

from an MRSA infection ranges from 20–30

percent and survivors are susceptible to

recurrent infections, slower response times

to treatments and longer hospital admissions.

As the principal investigator on a $48,225

grant from the Foundation for Healthy Living,

Dr. Lodise will examine different strains of

Health Care Associated MRSA and determine

against which ones vancomycin, the drug typi-

cally prescribed for treating MRSA, is likely to

be the most effective. He will be assisted in his

work by collaborators from Albany Medical

Center, the Buffalo V.A. Medical Center and

Strong Memorial Hospital in Rochester.

The team will identify different biological mark-

ers within each strain of Health Care Associated

MRSA and study how individual strains respond

to treatment with vancomycin. Ultimately, their

research will help health care professionals make

more informed decisions on the best courses

of treatment for MRSA patients. The study is

believed to be the first of its kind to examine

these types of markers in a statewide fashion.

Sufferers of chronic kidney disease (CKD) are

particularly susceptible to MRSA infections.

Between 1995 and 2002, dialysis centers

reported that the increase in incidences of

MRSA soared from 40 to 76 percent, with

vancomycin-resistant cases more than doubling.

Daptomycin, a new alternative to vancomycin,

may prove more successful in treating MRSA in

patients with CKD. But because drugs behave

differently in the bodies of patients being treat-

ed with dialysis versus healthy adults, it is diffi-

cult to know the appropriate dosing of dapto-

mycin. Without proper dosing guidelines, dialy-

sis patients may be exposed to either excess

medication or inadequate doses.

A $241,717 grant from Cubist Pharmaceuticals

will help Dr. Lodise and co-investigator Darren

Grabe ’95, Pharm.D., an associate professor in

the Department of Pharmacy Practice, study

patients undergoing hemodialysis—a procedure

used by nearly two-thirds of all sufferers of

end-stage kidney disease—and employ mathe-

matical modeling to determine the optimal

dosing requirements of daptomycin.

Dr. Lodise and Dr. Grabe are working together

with Katie Pallotta ’06, Pharm.D., and Nimish

Patel ’06, Pharm.D, from ACPHS, and Chris Hoy,

M.D., and Shari Meola, RN, from the Hortense

and Louis Rubin Dialysis Center, the outpatient

clinic used in the study.

Tackling a Serious Public Health ConcernLodise teams with ACPHS faculty and other collaborators on MRSA research

Dr. Lodise is working with Nimish

Patel ’06 to develop dosing guidelines

for patients with MRSA who are

undergoing dialysis.

There’s a killer on the loose in our hospitals and schools. Dr. Thomas Lodise and researchers at ACPHS and across the country are looking into ways to combat a deadly staph infection.


ACPHS 2008 // 19

A third antibiotic used to treat MRSA is linezol-

id, but many health care professionals choose

not to prescribe this medication, as it may lead

to Serotonin Syndrome in people who take

antidepressants. The syndrome may result in

changes in mental state, as well as neuromus-

cular disorders and overall body hyperactivity.

Because published data supporting increased

incidence of Serotonin Syndrome among

patients taking both linezolid and antidepres-

sant medications remain sparse, there is some

dispute about whether these drugs will interact

in a manner likely to cause the syndrome.

Patients who might react favorably to linezolid

may be prescribed a less effective course of

treatment to avoid the possibility of negative

side effects.

With a $25,000 grant from Pfizer, Dr. Lodise

will study the probability of linezolid and anti-

depressant drugs reacting in a manner that will

result in Serotonin Syndrome. If a connection

can be found, additional research will be done

to determine if certain patient populations are

at higher risks than oth-

ers for this outcome.

While the presence of

MRSA in health care

environments is not new,

its expansion in commu-

nity settings is a recent

and disturbing development. Outbreaks across

the country have made national headlines, and

the trend shows no sign of abating.

Today, more than half of all skin and soft tissue

infections are caused by MRSA. Most of these

patients are treated with antibiotics in an out-

patient setting, where a drug is typically deliv-

ered intravenously over a period of 10–14 days.

With a $154,656 grant from Cubist

Pharmaceuticals, Dr. Lodise will team with

Leon Cosler ’82, Ph.D., director of the Research

Institute for Health Outcomes at ACPHS, to

review a health claims database of patients treat-

ed for skin and soft tissue infections to examine

the effectiveness of vancomycin, daptotmycin

and linezolid, and determine if one of these med-

ications provides superior outcomes in treating

Community Associated MRSA infections.

“As the number of MRSA cases continues to

multiply across the country, the findings of

these research projects will hopefully help

inform health care professionals on how to

better treat afflicted patients and minimize

their suffering.”

Strains of MRSA (Methicillin-resistant

Staphylo-coccus aureus) bacteria, shown

here dividing, are increasingly resistant

to many antibiotic drugs.


The work being conducted by Dr. Lopes, with

the assistance of Jaclyn, focuses on the devel-

opment of liquid crystalline phases containing

the anti-cancer drug paclitaxel for the topical

treatment of cancers.

The research is particularly important to Jaclyn

who, as one of the first students to enter enroll

in the College’s new master’s degree program

in Pharmaceutical Sciences (MSPS) this fall,

will pursue her Pharm.D. and MSPS degrees

at ACPHS simultaneously.

“Medical research is something I have always

wanted to do and this will give me more flexi-

bility than a Pharm.D. alone,” Jaclyn says. “My

career goal is to work in the industry, develop-

ing drugs or delivery systems.”

Paclitaxel is a chemotherapeutic agent used

to treat several types of cancer. Though it can

be effective in treating skin cancers, including

Kaposi’s Sarcoma and basal cell carcinoma,

severe side effects have limited its usefulness.

Many HIV/AIDS patients suffer from Kaposi’s,

which is characterized by skin lesions that may

spread to the mouth, gastrointestinal tract and

respiratory tract. Presently, the disease is treat-

ed intravenously with paclitaxel with resultant

side effects such as low platelet count, hair loss

and joint pain. Hoping to overcome the drug’s

limitations, Jaclyn is assisting Dr. Lopes in

developing strategies to deliver paclitaxel

directly to the skin, and only the skin, via a

liquid crystalline phase, as this may optimize

drug localization within skin lesions while

eliminating the adverse effects.

“We are currently developing liquid crystalline

systems to enhance the penetration and local-

ization of paclitaxel in the skin while reducing its

transdermal delivery,” says Dr. Lopes. “Liquid crys-

talline phases consist of the state of matter whose

properties are intermediate between a crystalline

solid and a liquid. They look similar to gels, but

they have a very organized internal structure.”

“It doesn’t look like much, but when you get it

under a microscope, it looks really cool,” adds

Jaclyn. “If we can treat the cancer topically and

just get the drug to stay on the skin, we may

be able to significantly reduce the side effects.”

Jaclyn, who has worked with Dr. Lopes over

the past two academic years, says that there

is not much in the literature about the topical

use of paclitaxel. Her role in their pioneering

research currently involves in vitro studies

utilizing the skin from pigs’ ears; she then

measures the results using high-performance

liquid chromatography.

Typically, Jaclyn spends about 10 hours per

week in the lab, working on experiments either

with her mentor or by herself. This summer, the

team will commence in vivo research with rats.

Eventually Jaclyn says their work may focus on

attaching paclitaxel to peptides to deliver the

drug directly to the tumor site.

Last April, Jaclyn made a poster presentation,

which was considered for an award, at the

11th Annual American Association of

Pharmaceutical Scientists Northeast Regional

Discussion Group. The team recently submitted

an abstract to the Annual Meeting of the

Controlled Release Society, which will take

place in Copenhagen this July, and are hoping

to present there as well.

“Jackie is very smart and learns things very

fast,” Dr. Lopes says. “She is focused, commit-

ted and hard-working—qualities which will

allow her to excel in her professional life and

become an outstanding scientist!”

Assistant Professor Luciana Lopes and student Jaclyn Hosmer

are working to develop liquid crystalline systems to enhance the

effectiveness of the anti-cancer drug paclitaxel.

Third-year Pharm.D. student Jaclyn Hosmer ’12 has teamed with Assistant ProfessorLuciana Lopes in groundbreaking research that will hopefully lead to a new treatment—with fewer negative side effects—for various types of skin cancer.

Liquid crystalline phases

observed under a polarized

light mircoscope.

Skin deepTopical treatment offers new possibility for delivering anti-cancer drugs

Lamellar phase Hexagonal phase


ACPHS 2008 // 21


SCIENTIF IC METHOD

Enrichment Programs Inspire Next Generation of Scientists

Taylor Lanoue of Averill Park High School performs

a research experiment at PRI while Berne-Knox-Westerlo

student Justin Coon compiles the results.

Dr. Shaker Mousa, executive vice president and chairman of the Pharmaceutical Research

Institute at Albany College of Pharmacy and Health Sciences, in the lab with students Sabith

Choudhury of Hudson High School and Elizabeth Derderian of Averill Park High School.


ACPHS 2008 // 23

The College now offers three science enrich-

ment programs for students ranging from third

grade to seniors in high school. The newest of

these programs is the High School Research

Program which takes place throughout the

school year at the College’s Pharmaceutical

Research Institute (PRI).

This year, PRI will host more than 40 seniors

from 11 high schools across the Capital Region.

Shaker Mousa, Ph.D., executive vice president

and chairman of PRI, explains that shortly after

the Institute was founded in 2003, he began to

receive requests from friends and colleagues

who were interested in having their sons and

daughters participate in research at the

Institute. He happily obliged, and before long,

word began to spread among students and

teachers at high schools across the region

about this unique opportunity to work under

the direction of accomplished investigators.

“When schools contact me and say they are

looking to place students at PRI, I can’t say no.

I would feel miserable if I turned away some-

one who was interested in science. The child

that I turn away might be the one who finds a

cure to a disease and saves thousands of lives.”

says Dr. Mousa.

Depending on the individual school, students in

the research program are at PRI for six hours

per week for six weeks or four hours per week

for eight weeks. On the first day, Dr. Mousa

meets with them to discuss the parameters of

their projects, which may involve experimenting

with various types of medicines to compare their

effectiveness. Working in pairs, students spend

the first week orienting themselves to the labs

and learning basic research methodologies

before starting their projects. Students are

taught to work independently after the first

week, though research manager Majde Takieddin

remains nearby to supervise their activities,

answer questions and monitor their progress.

During the course of these sessions, they are

expected to gather, graph and analyze their

research data. In June, all of the students return

to PRI to formally present their findings to an

audience comprised of their parents, teachers

and peers.

“Many parents watch in disbelief as their chil-

dren present and defend their research,” says

Dr. Mousa. “They tell me, ’I can’t believe that

those words came from my child’s mouth!’”

Some of the students feel the same way. “I defi-

nitely didn’t think I could do this at the begin-

ning of the year,” said Andrea Nero, a student in

2007–08 program. “If I had seen the poster I

created, I would have thought that I could

never do something like that. But it is possible.”

The forerunner to the PRI program is the High

School Summer Research Program, an annual

program which marked its tenth year at ACPHS

this past summer. The program, in which rising

high school juniors and seniors pursue research

on campus, is overseen by David Clarke, Ph.D.,

chair of the Department of Arts and Sciences.

Five students from Albany and Troy High

Schools were selected to participate in the

2008 session.

In addition to the daily research activities, the

six-week program features “field trips” to sci-

ence and technology facilities such as Albany

Medical Center, Albany Molecular, Regeneron

and Mallinckrodt. ACPHS faculty assisting with

this year’s program included Dr. Mousa as well

as Carlton Campbell, Ph.D., Leon Cosler, Ph.D.,

Martha Hass, Ph.D., Luciana Lopes, Ph.D.,

Abdelhadi Rebbaa , Ph.D. and HaiAn Zheng,

Pharm.D.

As with the PRI program, students in the

summer program must present their research

to a gathering of faculty and staff and answer

questions related to their findings and

methodologies.

“Through the participation of numerous ACPHS

faculty and students as well as the cooperation

of local companies, the Summer Research pro-

gram is able to showcase the many opportuni-

ties available to students in the world of scien-

tific research. Without this type of exposure, it

is difficult for young people to understand the

range of exciting careers in the sciences,” says

Dr. Clarke.

At the opposite end of the age spectrum is the

ACPHS Academy program, which offers a

mathematic and scientific enrichment program

for local, at-risk students beginning in the third

grade and continuing through high school.

The program is designed to encourage stu-

dents at an early age to succeed and to build

confidence academically, particularly in math

and science. Reciprocally, ACPHS students ben-

efit by serving as mentors to these children, an

experience which helps enrich their overall edu-

cation and professional development.

The program was launched in 2006 with a

third-grade class from nearby Delaware

Community School. Students from that class,

now in fifth-grade, are matriculating through

the program, and this year they were joined by

a new class of third-graders from the Brighter

Choice Charter School. The participation of stu-

dents from Brighter Choice was made possible

through a gift of $250,000 from Thomas

D’Ambra, Ph.D., president and CEO of Albany

Molecular Research, and his wife, Connie.

The importance and need to fund these pro-

grams and others like them cannot be overstated.

“There is a crisis that exists in the U.S. when it

comes to getting young people interested in

science and technology. This is the greatest

country when it comes to technology, but we

are in a major decline, while countries such as

China and India are on the rise,” says Dr. Mousa.

“If we lose on science and technology, what is

left for us? We don’t want to reach that level.”

Albany College of Pharmacy and Health Sciences believes stronglythat part of its responsibility as an institution of higher learning isto foster and develop an interest in science among children.


Each summer, the Student Summer Research

Award Program at Albany College of Pharmacy

and Health Sciences awards internships that

provide a $2,000 stipend and free dormitory

housing to students in any of the degree pro-

grams at the College. This past summer, 10

students participated in the highly competitive,

eight-week program.

An awards ceremony held on October 3, during

Family Weekend, allowed members of the

ACPHS community and parents an opportunity

to see research presentations from participat-

ing students.

Leona Blustein, a sixth-year student, worked

with faculty mentor Sara Dugan, Pharm.D., to

do an assessment of substance use and abuse

among pharmacy students. Faculty members

Nicole Lodise and Jen Cerulli also assisted.

Leona, who hopes to do a general residency

or fellowship in psychiatry after earning her

Pharm.D., found that pharmacists are often

poorly trained to deal with alcohol and drug

abuse, and there is a need for more education

in this area.

Amanda Dihmess and Tom Lodise, Pharm.D.,

worked together on the molecular and clinical

epidemiology of carbapenem-resistant enter-

obacteriaceae. Carbapenems are a mainstay

in therapy against infections caused by gram-

negative bacteria. Amanda hopes to publish

her findings in the spring.

Third-year student Jaclyn Hosmer teamed with

Luciana Lopes, Pharm.D., Ph.D., on the develop-

ment of microemulsions containing paclitaxel

for the topical treatment of Kaposi’s Sarcoma, a

herpes virus-associated cancer. Many HIV/AIDS

patients suffer from Kaposi’s, presently treated

intravenously with resultant side effects (see

article page 20).

Elaine Liu worked with Alexandre Steiner,

Pharm.D., Ph.D., to research what happens

with a shift from fever to hypothermia during

Systemic Inflammatory Response Syndrome,

which can lead to multiple organ failure and death.

Fourth-year student Neil Mandalaywala contin-

ued work he had done during past summers

on Vitamin D-Up Regulated Protein. This time

he studied the role of VDUP-1 in tumor growth,

angiogenesis and metastasis at the

Pharmaceutical Research Institute alongside

Shaker Mousa, Ph.D., MBA.

Anjoli Punjabi and mentor Arnold Johnson,

Ph.D., did research at the V.A. Medical Center

in Albany on preventing septic shock as it

relates to the lungs, in particular studying the

role of tumor necrosis factor.

For the third summer in a row, Alexandra

Rehfuss ’09, who will earn her B.S. in

Pharmaceutical Sciences in May, focused

her work with Robert Levin, Ph.D., on the

treatment of interstitial cystitis and inconti-

nence in women.

Lastly, Peter Youssef presented on his work

with Martha Hass, Ph.D. Peter used his back-

ground in chemistry and developed a project

to analyze phospholipids not just qualitatively

but, for the first time, quantitatively.

Two ACPHS students, Tasmina Hydery ’10 and

Alex Villanueva ’09, have been awarded

American Foundation for Pharmacy Education

(AFPE) “Gateway to Research” Scholarships to

conduct research with Department of

Pharmaceutical Sciences faculty for the

2008–09 academic year. Considering that only

15 awards were given by AFPE nationwide, the

fact that two were granted to ACPHS students

speaks highly of the caliber of research being

done by these students in conjunction with

their faculty mentors.

Tasmina is working with mentor Robert Levin,

Ph.D. on a project entitled “Mechanism of the

protective effect of coenzyme Q10 and alpha

lipoic acid on obstructive urinary bladder dys-

function.

According to Dr. Levin, more than 60 percent

of all men over the age of 50 will develop weak

bladders as the result of an enlarged prostate,

which causes reduced blood flow to the blad-

der and the release of free radicals that dam-

age bladder muscle. Working with rabbits,

Tasmina’s research will try to determine if spe-

cific antioxidants will prevent the development

of weak bladders.

Alex has conducted research with Carlos

Feleder, Ph.D., on elucidating the role of endo-

cannabinoids in septic shock, which results in

an estimated 200,000 deaths each year in the

U.S. alone. Together they have discovered that

administration of Rimonabant, a cannabinoid

receptor antagonist, prior to administration of

shock-inducing lipopolysaccharide (LPS) blocks

shock-related hypotension.

Gateway to Research Scholarships provide out-

standing Pharm.D. students and undergraduates

in other science disciplines with support for a

faculty supervised research experience. The

program strives to attract the most talented stu-

dents to graduate study in the pharmaceutical

sciences by offering a rewarding undergraduate

research experience that includes a $4,000

stipend and $1,000 for supplies.

For more information on the program, visit

http://www.afpenet.org/

Awards Program RecognizesStudent Research

Gateway to ResearchSTUDENTS RECEIVE

PREST IG IOUS

SCHOLARSHIPS

STUDENT RESEARCH


ACPHS 2008 // 25

Native American studies are not generally the

first thing that comes to mind when thinking of

ACPHS. But a series of electives taken through

the Department of Arts and Sciences at the

College were influential in Philip Lubanski’s

decision to undertake an ambulatory care rota-

tion in the Navajo Nation.

Phil spent a month with the tribe last summer

at the Chinle Comprehensive Health Care

Facility (CCHCF) located on the Navajo Indian

Reservation in Arizona. Before embarking on

his Advanced Pharmacy Practice Experience,

the sixth-year Pharm.D. student took nearly all

of the College’s courses on Native Americans,

including one on Southwestern American Indians.

“These electives are what really sparked my

interest in the rotation,” Phil explains. “Learning

about the culture and actually living on the

reservation are two totally different things, but

Dr. [J. Daniel] d’Oney was very helpful in teach-

ing me about Navajo traditions and important

landmarks located near Chinle.”

The reservation, in the northeast corner of Arizona,

encompasses the famed Canyon de Chelly, site of

ancient Native American ruins and now home

to a living community of Navajo people.

“The Navajo really pride themselves on holding

on to their culture and language,” says Phil.

“Many of the patients I encountered there

spoke little or no English. For others, English

was their second language.”

Phil was assigned to the CCHCF, a part of the

Navajo Area Indian Health Service (IHS). A 60-

bed hospital, the facility serves as a health care

hub for the region. The pharmacy rotation has

accommodated a steady stream of ACPHS stu-

dents, says Director of Experiential Education

Laurie Briceland, Pharm.D., who was instrumen-

tal in establishing the practice site about 15

years ago.

“There are no ’traditional’ pharmacies on the

reservation, just a grocery store that sells some

common over-the-counter medications,” Phil

says. “The only pharmacies are in the IHS hospi-

tals and outpatient clinics. Most Navajo people

get all of their medications from the hospital,

including OTC medications like non-steroidal

anti-inflammatory drugs (NSAIDs).”

Phil’s primary responsibility at the clinic

was counseling, predominantly in the areas

of NSAIDs, antibiotic use and diabetes, the

most common medical problem faced by

the Navajo people.

“Diabetes is a huge issue on the reservation

and one that the IHS is working very hard to

get under control,” Phil explains. “By controlling

patients’ blood sugars, we can prevent further

complications down the road, such as neu-

ropathies, blindness and nephropathy.”

“Counseling really allowed a lot of interaction

with the Navajo people,” he adds. “Many folks

don’t have televisions, cable, internet access or

even newspapers, so the counseling they get at

the clinic is really all that many of them know

about their medications.”

There were several cultural differences Phil had

to be aware of when working with the tribe.

“The Navajo don’t speak of the deceased, so

[when taking a medical history] it is important

to look at a patient’s chart before asking about

their parents or grandparents, to make sure

that they haven’t passed away.”

He also had to be careful when explaining the

side effects of medications as many Navajo

believe that stating that something may hap-

pen in the future will cause the event to occur.

The hospital itself also differs from its off-reser-

vation counterparts. The CCHCF employs tradi-

tional healers for patients who request a Navajo

ceremony, which is then performed in a tradi-

tional Navajo building or ’hogan’ that is located

right on the hospital grounds.

“It was pretty neat trying to convey medication

information across cultural and educational bar-

riers. At times it was a bit challenging, but I

have not experienced a reward professionally

that rivals the feeling of knowing that you have

just taught someone something about their

medications or disease state that they couldn’t

have gotten anywhere else.”

Reservation Rotation Philip Lubanski ’09 Gains Experience in the Navajo Nation

The Navajo Indian Reservation encompasses Canyon de Chelly.


ASSETS

Cash and cash equivalents $ 14,801,492

Investments 10,586,516

Other assets 3,389,866

Accounts receivable—students 425,919

Receivables—government entities 1,583,276

Other receivables 539,782

Pledges receivable 1,145,057

Student loans receivable 2,391,585

Agency funds 200,958

Deposits with bond trustees 1,552,475

Property, plant & equipment—Net 45,602,328

Total assets $ 82,219,254

LIABILITIES AND NET ASSETS

Liabilities

Line of credit $ 0

Accounts payable and accrued liabilities 895,967

Deferred income and deposits 8,539,234

U.S. government grants refundable 2,133,125

Bonds payable 29,700,776

Capital lease obligation 0

Expected post retirement benefit obligation 830,251

Deposits held in custody for others 200,958

Total liabilities $ 42,300,311

Net Assets

UNRESTRICTED

For current operations $ 2,329,399

Funds functioning as an endowment 4,602,824

Designated for plant capital 7,000,000

Plant fund 19,585,915

Total unrestricted net assets $ 33,518,138

TEMPORARILY RESTRICTED

Unexpended funds received for restricted purposes $ 1,768,115

Total temporarily restricted net assets $ 1,768,115

PERMANENTLY RESTRICTED

Endowment funds $ 4,598,365

O’Brien Loan Fund 34,325

Total permanently restricted net assets 4,632,690

Total net assets 39,918,943

Total liabilities and net assets $ 82,219,254

BALANCE SHEET

Financials


RevenuesStudent Tuition and Fees 75.03%Government Contracts and Grants 8.43%Gifts and Pledges 4.86%Investment income 0.93%Postgraduate Education 0.30%Other Sources 1.65%Auxiliary Enterprises 8.80%100.00%

Expenses General Administration 17.48%Research 10.86%Student Financial Aid 1.46%Physical Plant 26.68%Institutional Advancement 3.94%Postgraduate Education 0.44%Investment losses 1.76%Instruction/Student Services 37.38%100.00%

ACPHS 2008 // 27

RevenuesStudent Tuition and Fees 75.03%Government Contracts and Grants 8.43%Gifts and Pledges 4.86%Investment income 0.93%Postgraduate Education 0.30%Other Sources 1.65%Auxiliary Enterprises 8.80%100.00%

Expenses General Administration 17.48%Research 10.86%Student Financial Aid 1.46%Physical Plant 26.68%Institutional Advancement 3.94%Postgraduate Education 0.44%Investment losses 1.76%Instruction/Student Services 37.38%100.00%

Government Contracts and Grants 8.43%

Auxiliary Enterprises 8.80%

Other Sources 1.65%

Postgraduate Education 0.30%

Investment Income 0.93%

Gifts and Pledges 4.86%

Student Tuition and Fees 75.03%

REVENUES

EXPENSES

General Administration 17.48%

Research 10.86%

Student Financial Aid 1.46%

Physical Plant 26.68%

Postgraduate Education 0.44%

Investment Losses 1.76%

Instruction/Student Services 37.38%

Institutional Advancement 3.94%


SCHOLARLY ACTIV ITY


ACPHS 2008 // 29

PUBLICATIONS

Chu F, Chou P, Mirkin BL, Mousa SA and RebbaaA. Cellular conditioning with Trichostatin Aenhances the anti-stress response through up-regulation of HDAC4 and down-regulation of theIGF/AKT pathway. Aging Cell, May 16, 2008 [Epubahead of print].

Al Sayegh FA Dr, Almahmeed W, Marashi M, BahrA, Mahdi HA, Bakir S, Alhumood S, Farhan MAand Mousa S. Global risk profile verification inpatients with venous thromboembolism inArabian Gulf Countries. Clinical and AppliedThrombosis/Hemostasis, April 8, 2008 [Epubahead of print].

Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA.Novel function of the thyroid hormone analogtetraiodothyroacetic acid: a cancer chemosensi-tizing and anti-cancer agent. Angiogenesis, April4, 2008 [Epub ahead of print].

Fares RR, Lansing LS, Gallati CA and Mousa SA.Antiplatelet therapy with clopidogrel and aspirinin vascular diseases: Clinical evidence for andagainst the combination. Expert Opinion onPharmacotherapy 9(3):377-86, February 2008.

Alsayegh F, Fakeir A, Alhumood S, Abdumalek K,Matar H, Samaul I, Nampoory N, Kabalawi H andMousa S. Use of recombinant activated factor VIIto arrest uncontrolled bleeding: A case series.Clinical and Applied Thrombosis/Hemostasis,Dec 26, 2007 [Epub ahead of print].

Mousa SA. Cell adhesion molecules: potentialtherapeutic & diagnostic implications. MolecularBiotechnology 38(1):33-40, January 2008.

Santulli RJ, Kinney WA, Ghosh S, Decorte BL, LiuL, Tuman RW, Zhou Z, Huebert N, Bursell SE,Clermont AC, Grant MB, Shaw LC, Mousa SA,Galemmo RA Jr, Johnson DL, Maryanoff BE andDamiano BP. Studies with an orally bioavailablealpha V integrin antagonist in animal models ofocular vasculopathy: retinal neovascularization inmice and retinal vascular permeability in diabeticrats. The Journal of Pharmacology andExperimental Therapeutics. 324 (3):894-901,March 2008.

Mousa SA, Bergh JJ, Dier E, Rebbaa A, O’ConnorLJ, Yalcin M, Aljada A, Dyskin E, Davis FB, Lin HYand Davis PJ. Tetraiodothyroacetic acid, a smallmolecule integrin ligand, blocks angiogenesisinduced by vascular endothelial growth factorand basic fibroblast growth factor. Angiogenesis11(2):183-90, 2008.

Mousa SA, Zhang F, Aljada A, Chaturvedi S,Takieddin M, Zhang H, Chi L, Castelli MC,Friedman K, Goldberg MM and Linhardt RJ.Pharmacokinetics and pharmacodynamics of oralheparin solid dosage form in healthy human sub-jects. Journal of Clinical Pharmacology47(12):1508-20, December 2007.

Amirkhosravi A, Meyer T, Amaya M, Davila M,Mousa SA, Robson T and Francis JL. The role oftissue factor pathway inhibitor in tumor growthand metastasis. Seminars in Thrombosis andHemostasis 33(7):643-52, October 2007.

Mousa SA, Bharali DJ and Armstrong D. Fromnutraceuticals to pharmaceuticals to nanophar-maceuticals: A case study in angiogenesis modu-lation during oxidative stress. MolecularBiotechnology 37(1):72-80, September 2007.

Qari MH, Aljaouni SK, Alardawi MS, Fatani H,Alsayes FM, Zografos P, Alsaigh M, Alalfi A,Alamin M, Gadi A and Mousa SA. Reduction ofpainful vaso-occlusive crisis of sickle cell anaemiaby tinzaparin in a double-blind randomized trial.Thrombosis and Haemostasis 98(2):392-6,August 2007.

Bharali DJ, Mousa SA and Thanavala Y. Micro- andnanoparticle-based vaccines for hepatitis B.Advances in Experimental Medicine and Biology601:415-21, 2007.

Mousa SA. Heparin, low molecular weight heparin,and derivatives in thrombosis, angiogenesis, andinflammation: emerging links. Seminars in Thrombosisand Hemostasis 33(5):524–33, July 2007.

Powell JA Jr. and Mousa SA. Neutrophil-activatingprotein-2- and interleukin-8-mediated angiogene-sis. Journal of Cellular Biochemistry102(2):412–20, October 2007.

Ovsag K, Hydery S and Mousa SA. Preferred druglists: Potential impact on health care economics.Vascular Health and Risk Management4(2):403–413, 2008.

GRANTS AND CONTRACTS

PROJECT: Evaluate the pharmacological activityof SelectX compounds in a panel of in vitro assays

SPONSOR: SelectX

TOTAL GRANT: $15,360

PROJECT PERIOD: 1/07–1/08

PROJECT: Role of 1, 6 Anhydo in Enoxaparin frac-tions in the modulation of endothelial tissue factorpathway inhibitor

SPONSOR: Aventis



PROJECT: Evaluations of anti-angiogenesis thy-roid hormone antagonists in cancer models

SPONSOR: Charitable Leadership FoundationMedical Technology Acceleration Program



PROJECT: Assay of iron and sucrose in samples

SPONSOR: Genix Pharma, Ltd.


PROJECT PERIOD: 12/31/06–12/07

PROJECT: Generation of tetrac conjugate poly-mers, physiochemical characterization, and initialstability assessment




PROJECT: Anti-angiogenesis efficacies ofTransMolecular lead TM601

SPONSOR: TransMolecular, Inc.



PROJECT: Kininogen in ocular angiogenesis-mediated disorders

SPONSOR: Vascular Vision PharmaceuticalsCo./NIH (Eye Institute and Cancer Institute)



PROJECT: Wound healing and haemostatic treat-ment using novel pharmaceutical nanopolymer ornanoparticles formulation of thyroid hormone T4analogs




PROJECT: Tissue factor/VIIa modulation in ocularangiogenesis

SPONSOR: Vascular Vision PharmaceuticalsCo./NIH (Eye Institute and Cancer Institute)



PROJECT: Cellular and molecular mechanisms ofTPH in the modulation of complement activationand inflammation

SPONSOR: Othera Pharmaceuticals, Inc.



PROJECT: Cellular and molecular mechanisms ofTPH in the modulation of complement activationand inflammation (amendment)




PROJECT: Neuronal protective effects and mech-anisms of Othera’s OT551 nanoparticles




PROJECT: Retinal neovascularization in infantmice in ROP

SPONSOR: Othera Pharmaceuticals, Inc



PROJECT: The effect of OT551 on nuclear factor-kB pathway activation




PROJECT: Funding for Postdoctoral fellow


TOTAL GRANT: $43,802 per year


Pharmaceutical Research Institute


PROJECT: Reversal of chemotherapy resistancewith Othera analogs




PROJECT: Assay of tetrac in plasma samples




PROJECT: In vitro evaluation of platelet activationby the test article in human blood

SPONSOR: Merck & Co., Inc.



PROJECT: Anti-angiogenesis and Anti-cancerefficacies and mechanisms of TM601

SPONSOR: Transmolecular, Inc.



PROJECT: PK/PD of OT304 and OT551 in ratCarrageenan-induced paw edema model




PROJECT: PK and PD evaluations of Othera’s leadcompounds in a Murine model of Endotoxin-induced Cytokine release




PROJECT: Evaluation of Othera’s leadCompounds in Murine model of Oxazolone-induced ear edema




PROJECT: Cancer and drug associated thrombo-sis




PROJECT: OT551 and OT304 nanoparticle formu-lation: Synthesis and characterization.




PROJECT: Enhancing the efficacy of chemothera-peutic breast cancer treatment with non-antico-agulant heparin

SPONSOR: U.S. Dept. of Defense Breast CancerResearch Program



PROJECT: Role of Pentasaccharide Fondaparinuxversus low molecular weight Heparin in woundhealing (Amended to study role in cancer-associ-ated thrombosis)

SPONSOR: Sanofi-Aventis and GlaxoSmithKline



PROJECT: Role of Heparin and Heparin deriva-tives beyond anticoagulation

SPONSOR: Sanofi-Aventis


DATES: 9/04–9/07

PROJECT: Role of Cathepsin inhibitors in angio-genesis and chemoresistance

SPONSOR: NSF-US-EGYPT Exchange Program


DATES: 9/07–8/09

PROJECT: Potent lipid mediators and ischemicheart diseases (Upstate New York TranslationalResearch Network—University of Rochester,Cornell University and PRI at ACPHS)

SPONSOR: Foundation for Healthy Living


DATES: 9/07–8/08

PROJECT: Othera XVII OT 304 effect on growthof doxorubicin resistant MCF7 cells in nude mice



DATES: 10/07–3/08

PROJECT: Othera XVIII-Efficacy of OT-304 inmice Xenograft models using drug-sensitive can-cer cell lines



DATES: 12/08–06/08

PROJECT: In Vitro study on extracorporeal filtra-tion system to remove oxaliplatin from bovineblood

SPONSOR: Delcath Systems


DATES: 12/07–11/08

PROJECT: Othera XVIIII-efficacy of OT-304 ongrowth of matrigel implanted pancreatic, ovarianand glioma cancer cells in nude mice



DATES: 02/08–09/08

PROJECT: Assay of over-sulfated ChondroitinSulfate in Heparin samples

SPONSOR: Medtronic Inc.


DATES: 4/08–5/08

PROJECT: Anti-angiogenesis efficacy of TM610against various pro-angiogenesis factors

SPONSOR: TransMolecular, Inc.


DATES: 6/08–12/08

PROJECT: Experimental models for testing noveltargets for pancreatic cancer cell invasion

SPONSOR: National Institutes of Health


DATES: 4/08–3/10

PROJECT: Evaluation of the anti-angiogenesisefficacy of Tetrac versus two different Tetracnanoformulations



DATES: 6/3/2008–6/13/2008

ABSTRACTS/PRESENTATIONS

XXIst Congress of the International Society onThrombosis and Haemostasis, Geneva,Switzerland, July 2007 (6 abstracts)

American Cancer Association, San Diego, Calif.,2008 (3 abstracts)

KeyStone Symposia, Breckinridge, Colorado,2008 (1 abstract)

Association for Research in Vision andOpthamology, Fort Lauderdale, Fla., April 2008 (3 abstracts)

7th International Haemostasis, Saudi Arabia, May 2008 (2 abstracts)

American Society of Clinical Oncology, Chicago,Ill., May 2008 (1 abstract)

American Thyroid Society Meeting, June 2008 (1 abstract)


ACPHS 2008 // 31

PUBLICATIONS

Machaon Bonafede

Bonafede M, Dick A, Noyes K, Klein JD and BrownT. The effect of acupuncture utilization on health-care utilization. Medical Care 46(1):41-8, January2008.

Nicole M. Stack Lodise

Stack NM and Zillich AJ. Implementation of inpa-tient and outpatient tobacco cessation programs.American Journal of Health-system Pharmacy64: 2074-2079, October 2007.

Thomas P. Lodise

Lodise TP, Pypstra R, Kahn JB, Murty BP, KimkoHC, Bush K, Noel G and Drusano GL. Probabilityof target attainment for ceftobiprole as derivedfrom a population pharmacokinetic analysis of 150 subjects. Antimicrobial Agents andChemotherapy 51:2378-2387, 2007.

Lodise TP, Miller CD, Patel N, Graves J andMcNutt LA. Identification of patients withPseudomonas aeruginosa respiratory tract infec-tions at greatest risk for carbapenem resistance.Infection Control and Hospital Epidemiology28(8):959–65, August 2007.

McGregor JC, Rich SA, Harris AD, Perencevich EN,Osih R, Lodise TP, Miller RR and Furuno JP. A sys-tematic review of the methods used to assess theassociation between appropriate antibiotic thera-py and mortality in bacteremic patients. ClinicalInfectious Diseases 45(3):329–37, August 2007.

Lodise TP, Kwa A, Cosler LE, Gupta R and SmithRP. Comparison of β-lactam and macrolide com-bination therapy vs. fluoroquinolone monotherapyin hospitalized Veteran Affairs’ patients with com-munity-acquired pneumonia. AntimicrobialAgents and Chemotherapy, August 2007 [Epubahead of print].

Lodise TP, Kinzig-Schippers M, Drusano GL, LoosU, Vogel F, Bulitta J, Hinder M and Sörgel F. Use ofpopulation pharmacokinetic modeling and MonteCarlo simulation to describe the pharmacody-namic profile of cefditoren in plasma and epithe-lial lining fluid. Antimicrobial Agents andChemotherapy 52(6):1945-51, June 2008.

Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RNand Sörgel F. Pharmacodynamics of ceftazidimeand meropenem in cerebrospinal fluid: Results ofpopulation pharmacokinetic modeling and MonteCarlo Simulation. Journal AntimicrobialChemotherapy 60:1038–44, November 2007.

Lodise TP, Patel N, Graves J, Kwa A, Furuno JP,Graffunder E, Lomaestro BM and McGregor JC.Predictors of 30-day mortality among patientswith Pseudomonas aeruginosa bloodstreaminfections: The impact of delayed appropriateantibiotic selection. Antimicrobial Agents andChemotherapy 51(10):3510–5, October 2007.

Lodise TP, McKinnon PS, Levine DP and RybakMJ. Impact of empirical therapy selection on out-comes of intravenous drug users with Methicillinsusceptible Staphylococcus aureus infectiveendocarditis. Antimicrobial Agents andChemotherapy 51(10):3731-3, October 2007.

Lodise TP, Nau R, Kinzig M, Jones RN and SörgelF. Comparison of the probability of target attain-ment between Ceftriaxone and Cefepime in thecerebrospinal fluid and plasma againstStreptococcus pneumoniae. DiagnosticMicrobiology and Infectious Disease58(4):445–52, August 2007.

Lodise TP and McKinnon PS. Outcomes and eco-nomic considerations with serious infections dueto Methicillin resistant Staphylococcus aureus.Pharmacotherapy 27(7):1001–12, July 2007.

Miller CD, El-Kholi R, Faragon J and Lodise TP.Prevalence and risk factors for clinically significantdrug interactions with antiretroviral therapy.Pharmacotherapy 27(10)1379–1386, 2007.

Lodise TP, Gotfried M, Barriere S and Drusano GL.Telavancin penetration into human epithelial liningfluid as determined by population pharmacokinet-ic modeling and Monte Carlo Simulation.Antimicrobial Agents and Chemotherapy, April2008 [Epub ahead of print].

Lodise TP, Lomaestro BM, Graves J and DrusanoGL. Larger Vancomycin doses are associated withan increased incidence of nephrotoxicity.Antimicrobial Agents and Chemotherapy 52(4);1330–6, April 2008.

Mohr JF, Peymann PJ, Troxell E, Lodise TP andOstrosky-Zeichner L. Risk factors for hyper-glycemia in hospitalized adults receivingGatifloxacin: A retrospective, nested case-con-trolled analysis. Clinical Therapeutics 30(1):152–7,January 2008.

Bhat SV, Peleg AY, Lodise TP, Shutt KA, CapitanoB, Potoski BA and Paterson DL. Failure of currentcefepime breakpoints to predict clinical outcomesfrom Gram negative bacteremia. AntimicrobialAgents and Chemotherapy 51(12):4390–5,December 2007.

Lodise TP, Patel N, Renaud-Mutart A, GorodeckyE, Fritsche TR and Jones RN. Pharmacokineticand pharmacodynamic profile of Ceftobiprole.Diagnostic Microbiology and Infectious Diseases61(1):96-102, May 2008.

Lodise TP and Neuhauser M. Community-associ-ated Methicillin-resistant Staphylococcus aureusin Pharmacotherapy Self-Assessment Program,Sixth Edition, Infectious Diseases (Dunsworth T,Richardson M, Chant C, Cheng JWM, ChessmanKH, Hume AL, et al, eds.), Lenexa, Kan.: AmericanCollege of Clinical Pharmacy, 37–54, 2008.

Lodise TP, Lomaestro BM and Drusano GL.Practical Application of pharmacodynamic princi-ples to optimize therapy and treat resistantorganisms: A focus on Beta-Lactam antibiotics inAntimicrobial Resistance: Problem Pathogensand Clinical Countermeasures (Owens RC andLautenbach E, eds.), New York, N.Y.: InformaHealthcare USA, Inc., 317–335, 2008.

McKinnon PS and Lodise TP. Outcomes and costconsiderations with MRSA infections. in MRSA(Weigelt J, ed.), New York, N.Y.: InformaHealthcare USA, Inc., 189–211, 2008.

Patel N, McNutt LA and Lodise TP. The relation-ship between varying prior antibiotic exposuredefinitions and piperacillin/tazobactam resistanceamong patients with Pseudomonas aeruginosarespiratory tract infections. Antimicrobial Agentsand Chemotherapy, June 2008 [Epub ahead ofprint].

Teresa J. Lubowski

Lubowski TJ, Cronin LM, Pavelka R., Briscoe-Dwyer L. and Hamilton RA. A medication recon-ciliation project conducted by Pharm. D. studentsduring an APPE in a multi-site health system.American Journal of Pharmaceutical Education71 (5): Article 94, 2007.

Margaret Malone

Malone M. The obesity pandemic: How did we gethere? The Annals of Pharmacotherapy 41:1497–8,2007.

Cerulli J and Malone M. Women’s health promo-tion within a community advanced pharmacypractice experience. American Journal ofPharmaceutical Education 72(2):Article 25, 2008.

Alger-Mayer S, Polimeni J and Malone M. Pre-operative weight loss as a predictor of long termsuccess following Roux-en-Y gastric bypass.Obesity Surgery, April 2008 [Epub ahead of print].

Alger-Mayer S. Rosati C, Polimeni J and MaloneM. Pre-operative binge eating status and gastricbypass surgery. Obesity Surgery, May 2008[Epub ahead of print].

John M. Polimeni

Polimeni JM. Assessment of the economics cur-riculum at a college of pharmacy. Journal ofCollege Teaching and Learning 4(10):47–56,October 2007.

Polimeni JM and Polimeni RI. Energy consumptionin transitional economies (Part I): Jevons’ Paradoxfor Romania, Bulgaria, Hungary and Poland.Romanian Journal of Economic Forecasting4(3):63-80, September 2007.

Polimeni RI and Polimeni JM. Multi-scale integrat-ed analysis of societal metabolism and Jevons’Paradox for Romania, Bulgaria, Hungary andPoland (Part II). Romanian Journal of EconomicForecasting 4(4):61–76, December 2007.

Onyeiwu S, Polimeni RI and Polimeni JM.Distributional impact of globalization-inducedmigration: Evidence from a Nigerian Village.WIDER Research Paper 66, October 2007.

Onyeiwu S, Polimeni RI and Polimeni JM.Distributional impact of globalization-inducedmigration: Evidence from a Nigerian Village.African Development Review 20(1):115–34, April2008.

Polimeni JM. Jevons’ Paradox: A case study ofChina. International Journal of InterdisciplinarySocial Sciences 2(2): 383–394, 2007.

Polimeni RI and Polimeni JM. Structural adjust-ment and the Igbo extended family. InternationalJournal of the Humanities 5(4):77-82, 2007.

Polimeni RI and Polimeni JM. Multi-scale integrat-ed analysis of societal metabolism: The case ofRomania. International Journal ofInterdisciplinary Social Sciences 2(2):41–51, 2007.

Polimeni JM. Protecting the global food supplyfrom a terrorist attack. International Journal ofthe Humanities 5(4):71–75, 2007.

Polimeni JM. Assessment of the economics cur-riculum at a college of pharmacy. Journal ofCollege Teaching & Learning, 4(10):47–56, 2007.

Polimeni JM. Jevons’ Paradox and the economicimplications for Europe. International Businessand Economics Research Journal, 6(10):109–119,2007.

Polimeni JM, Mayumi K, Giampietro M and AlcottB. The Jevons’ Paradox: The Myth of ResourceEfficiency Improvements. London, U.K: EarthscanPublications, Ltd., January 2008.

Pharmacy Practice



Machaon Bondafede

Guilbert T, Schatz M, Davis EA, Tomaszewski KJand Bonafede M. Health care utilization is higheramong patients whose asthma is not well-con-trolled: Evidence from a large longitudinal cohort.American Academy of Allergy Asthma andImmunology Annual Meeting, Philadelphia, Pa.,March 2008.

Garris C, Schatz M, Guilbert T, Davis EA, Bonus Tand Bonafede M. Asthma control is predictive ofhealth-related quality of life: Survey using theAsthma Control Test™ and Childhood AsthmaControl Test™. American Academy of AllergyAsthma and Immunology Annual Meeting,Philadelphia, Pa., March 2008.

Michael R. Brodeur

Brodeur MR. Medications and older adults with afocus on dysphagia. New York State DisabilityServices and Organizations, Syracuse N.Y.,September 2007.

Brodeur MR. Anticholinergic medications andolder adults. Continuing Education Program,Albany College of Pharmacy, Albany, N.Y.,September 2007.

Brodeur MR. Diphenhydramine and tetracaine.Colonie Emergency Medical Services, Albany, N.Y.,September 2007.

Brodeur MR and Pannenton K. Anticholinergicmedications. Island Peer Review Organization(IPRO) Teleconference, New York State,November 2007.

Brodeur MR. Naloxone. Colonie EmergencyMedical Services, Albany, N.Y., January 2008.

Brodeur MR and Saffel D. Proton pump inhibitors:Point, counterpoint. American Medical DirectorsAssociation, Salt Lake City, Utah, March 2008.

Jennifer Cerulli

Cerulli J. Community pharmacy practice initiativeto support the identification and education ofpeople with Chronic Obstructive PulmonaryDisease. American Pharmacists Association 2008Annual Meeting and Exposition, San Diego, Calif.,March 2008.

Angela C. Dominelli

Bruce SP, Schwartz A and Dominelli A. Survey ofcurricular changes. Annual Meeting of theAmerican Association of Colleges of Pharmacy,Orlando, Fla., July 2007.

Gina D. Garrison

Garrison GD, Strang AF, Rivers S and LubowskiTJ. A pharmacy student based coronary heart dis-ease (CHD) risk assessment service in the ambu-latory care setting: Patient and student outcomes.American Association of Colleges of PharmacyAnnual Meeting, Orlando, Fla., July 2007.

Garrison GD. Pharmaceutical industry influence atan academic medical center. Department ofMedicine Grand Rounds, Albany Medical Center,Albany, N.Y., September 2007.

Garrison GD. Dyknow educational technology usein the large or small classroom: Sharing the expe-rience. Fall 2007 Capital District EducationalTechnology Group Conference, Albany College ofPharmacy, Albany, N.Y., October 2007.

Garrison GD. Cardiovascular risk factors.Continuing Education program, PharmacistsSociety of the State of New York Mid-winterConference, Saratoga Springs, N.Y., January 2008.

Garrison GD. Ties that bind: Professional relation-ships with pharmaceutical industry. PharmacyPractice Institute, Albany College of Pharmacy,Albany, N.Y., March 2008.

Garrison GD. Ties that bind: Professional relation-ships with industry. St. Peters Hospital MedicalGrand Rounds, Albany, N.Y., April 2008.

Garrison GD. Keynote address. Beta Theta chap-ter induction, Rho Chi Pharmacy Honor Society,Arnold and Marie Schwartz College of Pharmacyand Health Sciences, Long Island University—Brooklyn Campus,. Brooklyn, N.Y., May 2008.

Nicole M. Lodise

Lodise NM. Tobacco cessation in the inpatient set-ting. Greater New York Hospital Association, EastElmhurst, N.Y.,October 2007.

Lodise NM. Nicotine dependence and treatment:A look at the myths and facts. Addiction MedicineInstitute, Albany Medical Center, Albany, N.Y.,November 2007.

Lodise NM. Cervical cancer and the HPV vaccine.Pharmacy in the News Continuing Education pro-gram, Albany College of Pharmacy, Albany, N.Y.,November 2007.

Lodise NM. Tobacco cessation for the busy clini-cian. Albany Medical Center OB/GYN GrandRounds, Albany, N.Y., November 2007.

Lodise NM. How to incorporate tobacco cessationinto a busy setting. New York State Council ofHealth-system Pharmacists Winter Conference,Killington, Vt., January 2008.

Thomas P. Lodise

Lodise TP, Lomaestro BM, Graves J and DrusanoGL. Higher empirical Vancomycin dosing is associ-ated with increased nephrotoxicity. 45th AnnualMeeting of the Infectious Diseases Society ofAmerica, San Diego, Calif., October 2007.

Lodise TP, Graves J, Evans A, Graffunder E,Helmecke M and Stellrecht K. Predictors ofVancomycin treatment failure among patientswith MRSA bacteremia. 45th Annual Meeting ofthe Infectious Diseases Society of America, SanDiego, Calif., October 2007.

Lodise TP, Lomaestro B, Kwa A and Drusano GL.Pharmacodynamics of extended infusionPiperacillin/Tazobactam against Pseudomonasaeruginosa. 45th Annual Meeting of the InfectiousDiseases Society of America, San Diego, Calif.,October 2007.

Helmecke M, Graves J, Evans A, Graffunder E,Stellrecht K and Lodise TP. Predictors ofVancomycin MIC ³ 2 mg/L among patients withMRSA bacteremia. 45th Annual Meeting of theInfectious Diseases Society of America, SanDiego, Calif., October 2007.

Drusano GL, Ambrose PG, Bhavnani SM, LodiseTP, Rubino CM, Forrest A, Louie A and RodvoldKA. Vancomycin dose recommendations for hos-pital-, ventilator- or health care- associated pneu-monia and the attainment of Vancomycin throughconcentrations of 15-20 mg/L: CognitiveDissonance. 45th Annual Meeting of theInfectious Diseases Society of America, SanDiego, Calif., October 2007.

Miller C, El-Kholi R, Lodise TP and Fish D.Virologic and immunologic efficacy ofDidanosine/Tenofovir as a NRTI backbone withinPI-based HAART. 47th Interscience Conferenceon Antimicrobial Agents and Chemotherapy,Chicago, Ill., September 2007.

Patel N, Graffunder E, Evans A, Helmecke M,Stellrecht K and Lodise TP. Relationship betweenhVISA and outcomes among patients with MRSAbloodstream infections treated with Vancomycin.18th European Congress of Clinical Microbiologyand Infectious Diseases, Barcelona, Spain. April2008.

Patel N, Graffunder E, Evans A, Helmecke M,Stellrecht K and Lodise TP. Predictors of hVISAamong patients with MRSA bacteremia. 18thEuropean Congress of Clinical Microbiology andInfectious Diseases, Barcelona, Spain. April 2008.

Patel N and Lodise TP. Predictors of piperacillin-resistant Pseudomonas aeruginosa amongpatients with respiratory tract infections: The pre-dictive value of varying exposure definitions andthe risk of multiple prior antibiotic exposures.18thEuropean Congress of Clinical Microbiology andInfectious Diseases, Barcelona, Spain. April 2008.

Lodise TP. Continuous and short-term infusionstrategies. Making a Difference in InfectiousDiseases Pharmacotherapy Annual Conference,Orlando, Fla., May 2008.

Lodise T. Resistant gram-negative infections: Newtreatment approaches—Improving the outcomewith PK/PD. Making a Difference in InfectiousDiseases Pharmacotherapy Annual Conference,Orlando, Fla., May 2008.

Lodise T. Treatment of MRSA: New and improvedversus old and reliable. Continuing Education pro-gram, Albany College of Pharmacy, Albany, N.Y.,April 2008.

Lodise T. MRSA Update. Continuing Educationprogram, Albany College of Pharmacy, Albany,N.Y., February 2008.

Teresa J. Lubowski

Lubowski TJ and Cerulli J. Quality assurance pro-gram for pharmacy practice experiences usingCAPE-based capabilities checklists. AmericanAssociation of Colleges of Pharmacy, Orlando,Fla., July 2007.

Margaret Malone

Malone M. Altered drug disposition after bariatricsurgery. Treatment options for obesity: Focus ses-sion on bariatric surgery. American College ofClinical Pharmacy Spring Practice and ResearchForum, Phoenix, Ariz., April 2008.

Macary W. Marciniak

Marciniak MW and Malone D. NationalImmunization Awareness Month /APhA-ASPOperation Immunization, Schenectady Today—Wednesday Edition (live interview), August 2007

Marciniak MW. Patient-centered care to minimizecardiovascular risk: How to fit outcomes monitor-ing in the busy community pharmacy practice.Continuing Education Program, Albany College ofPharmacy, Albany, NY, August 2007.

Marciniak MW and Davison L. AmericanPharmacists Month, SchenectadyToday–Wednesday Edition (live interview),October 2007.


ACPHS 2008 // 33

Marciniak MW. Pharmacist and student pharma-cist perceptions of the self-care championship.Nonprescription Medicines Academy, Cincinnati,Ohio, October 2007.

Marciniak MW. Navigating through the pharmacyresidency process, American PharmacistsAssociation—Academy of Student Pharmacists(APhA-ASP) Midyear Regional Meeting, Denver,Colo., October 2007.

Marciniak MW. Progress report: Providing clinicalpharmacy services in chain pharmacies. AmericanCollege of Clinical Pharmacy Annual Meeting,Denver, Colo., October 2007.

Marciniak MW. The role of pharmacist as immuniz-er. Nassau/Suffolk Adult ImmunizationConference, Melville, N.Y., October 2007.

Marciniak MW. Navigating through the pharmacyresidency process, American PharmacistsAssociation - Academy of Student Pharmacists(APhA-ASP) Midyear Regional Meeting, Albany,N.Y., October 2007.

Marciniak MW. Pharmacists as immunizers. NewYork Chapter of the American College ofPhysicians Scope of Practice Forum, Syracuse,N.Y., October 2007.

Marciniak MW. Immunization and the pharmacist.Albany College of Pharmacy Annual Law Day,Albany, N.Y., November 2007.

Marciniak MW and White L. AmericanPharmacists Association Pharmacy-basedImmunization Delivery Certificate TrainingProgram. Pharmacists Society of the State of NewYork Midwinter Conference, Saratoga Springs,N.Y., January 2008.

Marciniak MW. Medicare Modernization Act: OTCsto get through the gap. Virginia PharmacistsAssociation Mid-Year Conference, Charlottesville,Va., February 2008.

Marciniak MW. Pharmacists as immunizers:Testimony provided on avian influenza and the“Pharmacists as Immunizers” bill. New York CityCouncil Committee on Health, New York, N.Y.,February 2008.

Marciniak MW and Rothholz MC. Immunizationsand the pharmacist. Institute for ContinuingEducation/1199 SEIU League Training andUpgrading Fund, New York, N.Y., March 2008.

Marciniak MW. Medication Therapy Management.Press briefing for the release of MedicationTherapy Management in Pharmacy Practice:Core Elements of an MTM Service Model Version2.0, San Diego, Calif., March 2008.

Marciniak MW. Medication Therapy Management:New help for prescription med questions.Television interview for San Diego NBC, SanDiego, Calif., March 2008.

Marciniak MW. Pharmacists as immunizers.Television interview broadcast toAssemblywoman Amy Paulin’s 88th AssemblyDistrict, Westchester, N.Y., March 2008.

Marciniak MW. Pharmacists administering influen-za and pneumococcal vaccines to adults in NewYork State. Roundtable discussion sponsored byAssemblyperson Deborah Glick, New YorkAcademy of Medicine, New York, N.Y., May 2008.

Christopher D. Miller

Miller CD. Antiretroviral therapy in 2007. KinneyDrug Regional Office, Syracuse, N.Y., September2007.

Miller C. Approach to salvage and treatment-experienced patients with HIV. New York StateDepartment of Corrections, Albany, N.Y., January2008.

Miller C. What’s bugging you? Influenza vaccineand therapy. Annual Pulmonary Update, Albany,N.Y., January 2008.

John M. Polimeni

Polimeni JM. Analysis of medicinal drugs asgroundwater pollutants and a possible solution.Seminar of the School of Doctorate Studies in thePharmacological Sciences, Department ofFarmacology and Anestesiolgy, Universita’ DegliStudi di Padova, September 2007.

Polimeni JM. Institutions and organizations in theEuropean agri-food systems: Economic and soci-ological approaches. Universita’ Degli Studi diPerugia, Facolta’ di Agraria, Perugia, Italy,September 2007.

Polimeni JM, Cosler LE, Chandrasekara R andDobis M. A theoretical approach to reduce dis-carded pharmaceuticals in the environment.Fourth International Conference onEnvironmental, Cultural, Economic and SocialSustainability, Universiti Malaysia, Terengganu,Malaysia, January 2008.

Polimeni J. Structural adjustment, economicdevelopment and vulnerability: Evidence fromtwo Nigerian communities. 34th AnnualConference of the Eastern Economic Association,Boston, Mass., March 2008.

Polimeni J, Dobis M and Cosler LE. A cost-effec-tiveness analysis of a prescription and over-the-counter drug take-back program for New YorkState. 2007 Northeast Water Science Forum,Portland, Me., August 2007.

Polimeni J. Analysis of medicinal drugs as ground-water pollutants and a possible solution. Seminarof the School of Doctorate Studies in thePharmacological Sciences, Universita’ Degli Studidi Padova, Padua, Italy, September 2007.

Aimee F. Strang

Strang A, Bruce SP, Grabe D and Dominelli A.Mapping of pharmacotherapy outcomes: Anassessment-based strategy. Annual Meeting ofthe American Association of Colleges ofPharmacy. Orlando, Fla., July 2007.

Sarah L. Scarpace

Scarpace, SL. Ralox! The FDA approved it! SERMSfor chemoprevention. Barbara DiLascia LectureSeries on Womens’ Health, Albany College ofPharmacy, Albany, N.Y., October 2007.

Scarpace SL. Board Certified OncologyPharmacist presentation on Head/Neck Cancers.Hematology Oncology PharmacistsAssociation/International Society of OncologyPharmacy Practitioners 2008 Conference,Anaheim, Calif., June 2008.

Scarpace SL. Optimizing anti-emetics forchemotherapy-induced nausea/vomiting. ACPContinuing Education program: Annual PharmacyPractice Institute, Albany, NY. March 2008.

Tanya Vadala

Vadala T and Flynn A. NYS Board review. PSSNY,Saratoga Springs, N.Y., January 2008.

GRANTS

Leon E. Cosler

PROJECT: Regional variation in cancer-care treat-ment and outcomes

SPONSOR: ACP Scholarship of Discovery andEducational Excellence Grant

CO-INVESTIGATORS: Sarah Scarpace, MachaonBonafede and Steve Szebenyi


GRANT PERIOD: 2008–2009

Sara E. Dugan

PROJECT: AACP Annual Meeting

SPONSOR: 2008 Wal-Mart Annual ConferenceScholarship Program

CO-AWARDEE: Leona Blustein

TOTAL GRANT: $1,000

Gina Garrison

PROJECT: AACP Annual Meeting

SPONSOR: 2008 Wal-Mart Annual ConferenceScholarship Program

CO-AWARDEE: Whitney Caron

TOTAL GRANT: $1,000


PUBLICATIONS

Richard E. Dearborn Jr.

Mandalaywala NV, Chang S, Snyder RG,Levendusky MC, Voigt JM and Dearborn Jr. RE.The tumor suppressor vitamin D3 up-regulatedprotein 1 (VDUP1) functions downstream of REPOduring Drosophila gliogenesis. DevelopmentalBiology 315(2):489–504, March 2008.

Carlos Feleder

Yilmaz MS, Millington WR and Feleder C. Thepreoptic anterior hypothalamic area mediates thehypotensive response induced by lipopolysaccha-ride in male rats. Shock 29(2):232–7, February2008.

Pallares EM, Shmuckler J, Scacchi P, Feleder Cand Cutrera RA. Effects of prenatal stress onmotor performance and anxiety behavior in swissmice. Physiology and Behavior 92:951–956, 2007.

Gail Goodman Snitkoff

Goodman Snitkoff G. Common infectious diseasesand immunization in Concepts in Immunologyand Immunotherapeutics, 4th Edition (B. Smith,ed.), Bethesda, Md.: American Society of Health-System Pharmacists, 2008.

Goodman Snitkoff G. Immunology inComprehensive Pharmacy Review, 7th Edition (L.Shargel, ed.), Philadelphia: Lippincott, Williamsand Wilkins, 2008.

Goodman Snitkoff G. Microbiology inComprehensive Pharmacy Review, 7th Edition.(L. Shargel, ed.), Philadelphia: Lippincott, Williamsand Wilkins, 2008.

Robert M. Levin

Palmieri K, Mannikarottu AS, Chichester P, KoganB, Leggett RE, Whitbeck C and Levin RM. Theeffects of cyclical estrogen on bladder and ure-thral structure and function. British Journal ofUrology 99:171–176, 2007.

Whitbeck V, Chichester P, Sokol R and Levin RM.Role of nitric oxide in urinary bladder function:Effect of L-Arginine in the presence and absenceof partial outlet obstructions. UrologiaInternationalis 78:30–36, 2007.

Arecht MM, Chichester P, Michel MC and LevinRM. Effect of short-term outlet obstruction on ratbladder nerve density and contractility.Autonomic and Autacoid Pharmacology27:47–53, 2007.

Lin AD, Mannikarottu AS, Kogan BA, Whitbeck C,Leggett RE and Levin RM. Effect of bilateral in-vivo ischemia/reperfusion on the activities ofsuperoxide dismutase and catalase: Response toa standardized grape suspension. Molecular andCellular Biochemistry 296:11–16, 2007.

Agartan CA, Leggett RE, Kogan BA and Levin RM.Effect of age on the response to in-vitro ischemiaof the rabbit bladder. Urologia Internationalis78:155–159, 2007.

Onal B, Levin RM, Kogan BA, Whitbeck C andMannikarottu AS. Effect of maturation and age onestrogen induced functional hypertrophy of thefemale rabbit bladder. BJU International99(3):674-679, March 2007.

Guven A, Whitbeck C, Chichester P, Leggett RE,Kogan BA, Mannikarottu AS and Levin RM. Effectof age on the response to short term partial blad-der outlet obstruction in the rabbit. BJUInternational 100(4):930–934, October 2007.

Juan Y-S, Onal B, Broadway S, Cosgrove J,Leggett RE, Whitbeck C, De E, Sokol R and LevinRM. Effect of castration on male rabbit lower uri-nary tract tissue enzymes. Molecular and CellularBiochemistry 301:227–233, 2007.

Lin W-Y, Rehfuss A, Whitbeck C, Juan W-S,Chichester P, Mannikarottu AS and Levin RM.Effect of Letrozole on female rabbit urinary blad-der function. BJU International 100(6):1391–1395,December 2007.

Lin W-Y, Levin RM, Chichester P, Leggett RE, JuanY-S, Johnson A, Neuman P, Whitbeck C, Guven A,Kogan BA and Mannikarottu AS. Effects of L-Arginine and L-NAME on chronic partial bladderoutlet obstruction in the rabbit. American Journalof Physiology. Regulatory, Integrative andComparative Physiology 293:2390-2399, 2007.

Guven A, Kalorin C, Onal B, Whitbeck C,Chichester P, Kogan BA, Levin RM andMannikarottu AS. Novel biomarkers of bladderdecompensation after partial bladder obstruction.Neurourology and Urodynamics 26:1036–1042,2007.

Juan Y, Lin W, Kalorin C, Kogan B, Levin RM andMannikarottu AS. The effect of partial bladderoutlet obstruction on carbonyl and nitrotyrosinedistribution in rabbit bladder. Urology70:1249–1253, 2007.

Onal B, Levin RM, Kogan BA, Guven A, LeggettRE and Mannikarottu AS. Novel alterations insuperoxide dismutase and catalase activities inthe female rabbit bladder subjected to hormonalmanipulations. International Urology andNephrology 39(4):1049-1054, 2008.

Chou EC, Whitbeck C, Herz J, Demopulos GA andLevin RM. The effect of intravesical ketoprofen onAcetylcholine-evoked urinary bladder contractilityand detrusor overactivity in the anesthetized rab-bit model. International Urology and Nephrology39(4):1055–1059, 2007.

Chou EC, Whitbeck C, Borow A, Burden O, Mays Pand Levin RM. The effect of intravesical ketopro-fen on Ach-evoked urinary bladder contractilityand hyperreflexia in the anesthetized rabbitmodel.

Lin WY, Guven A, Juan YS, Johnson A, Neuman P,Whitbeck C, Chichester P, Kogan B, Levin RM andMannikarottu AS. Free radical damage as a bio-marker of bladder dysfunction after partial outletobstruction and reversal. BJU International101:621–626, 2008.

Levin RM, Juan Y-S, Whitbeck C., Perez-MartinezFC and Lin WY. The effect of Darifenacin on over-active bladder in female and male rabbits.International Urology and Nephrology [EPubahead of print, August 7, 2007].

Guven A, Lin WY, Leggett RE, Kogan BA, LevinRM and Mannikarottu A. Effect of aging on theresponse of biochemical markers in the rabbitsubjected to short-term partial bladder obstruc-tion. Molecular and Cellular Biochemistry306(1–2):213-9, December 2007.

Lin WY, Mannikarottu A, Chichester P, Guven A,Johnson A, Neuman P, Juan YS, Schuler C, KoganBA, and Levin RM. Changes in the smooth muscleof the corpora cavernosum related to reversal ofpartial outlet obstruction in rabbits. Journal ofAndrology 29(2):164–71, Mar–April 2008.

Juan YS, Mannikarottu AS, Hydery T, Lin WY,Kogan BA, Whitbeck C, Leggett RE and Levin RM.Coenzyme Q10 protect against ischemia / reper-fusion induced biochemical and functionalchanges in rabbit urinary bladder. Molecular andCellular Biochemistry 311(1–2):73-80, April 2008.

Lin WY, Rehfuss A, Whitbeck C and Levin RM.Effect of co-enzyme Q10 and α-lipoic acid on theresponse of the rabbit urinary bladder to repeti-tive stimulation and in vitro ischemia. Urology72(1):214–9, 2008.

Arnold Johnson

Gertzberg N, Gurnani T, Neumann P, Forbes AK,Jean-Louis N and Johnson A. Tumor necrosis fac-tor-± (TNF) causes barrier dysfunction mediatedby tyrosine98 and tyrosine218 in β-actin.American Journal of Physiology: Lung Cellularand Molecular Physiology 293(5):L1219–L29,August 2007.

Lin WY, Levin RM, Chichester P, Leggett R, JuanYS, Johnson A, Neumann P, Whitbeck C, Guven A,Kogan B and Mannikarottu A. Effects of L-arginineand L-NAME on chronic partial bladder outletobstruction in rabbit. American Journal ofPhysiology: Regulatory, Integrative andComparative Physiology 293(6):R2390–R9,October 2007.

Luciana B. Lopes

Lopes LB, Furnish E, Komalavilas P, Seal BL,Panitch A, Bentley MV and Brophy CM. Enhancedskin penetration of P20 phosphopeptide usingprotein transduction domains. European Journalof Pharmaceutics and Biopharmaceutics68(2):441-5, February 2008.

Komalavilas P, Penn RB, Flynn CR, Thresher J,Lopes LB, Furnish EJ, Guo M, Pallero MA, Murphy-Ullrich JE and Brophy CM. The small heat shock-related protein, HSP20, is a cAMP-dependentprotein kinase substrate that is involved in airwaysmooth muscle relaxation. American Journal ofPhysiology. Lung, Cellular and MolecularPhysiology 294(1):L69–78, January 2008.

William R. Millington

Yilmaz MS, Millington WR and Feleder C. The pre-optic anterior hypothalamic area mediates initia-tion of the hypotensive response induced bylipopolysaccharide in male rats. Shock29(2):232–237, 2008.

Millington WR. Sheep have the last word: Kappaand delta opioid receptors initiate hemorrhagichypotension. Acta Physiologica 191:1, 2007.

Millington WR and Göktalay G. Neurochemicalapproaches to addiction treatment in Pain andChemical Dependency (H. Smith H and S. Passik,eds.), New York: Oxford University Press, 2008.

Alexandre A. Steiner

Steiner AA, Turek VF, Almeida MC, Burmeister JJ,Oliveira DL, Roberts JL, Bannon AW, Norman MH,Louis JC, Treanor JJ, Gavva NR and RomanovskyAA. Nonthermal activation of transient receptorpotential vanilloid-1 channels in abdominal visceratonically inhibits autonomic cold-defense effec-tors. The Journal of Neuroscience 27:7459–7468,2007.

Pharmaceutical Sciences


ACPHS 2008 // 35

Ootsuka Y, Blessing WW, Steiner AA andRomanovsky AA. Fever response to intravenousprostaglandin E2 is mediated by the brain butdoes not require afferent vagal signaling.American Journal of Physiology. Regulatory,Integrative and Comparative Physiology294:R1294–R1303, 2008.

Jeffrey M. Voigt

Mandalaywala NV, Chang S, Snyder RS,Levendusky MC, Voigt JM and Dearborn Jr. RE.The tumor suppressor, vitamin D3 up-regulatedprotein 1 (VDUP1), functions downstream of REPOduring Drosophila gliogenesis. DevelopmentalBiology 315:489-504, 2008.

M. Sertac Yilmaz

Yilmaz MS, Millington WR, and Feleder C. Thepreoptic anterior hypothalamic area mediates ini-tiation of the hypotensive response induced byLPS in male rats. Shock 29(2):232–237, 2008.

Cansev M, Yilmaz MS, Ilcol YO, Hamurtekin E andUlus IH. Cardiovascular effects of CDP-cholineand its metabolites: involvement of peripheralautonomic nervous system. European Journal ofPharmacology 577:129–142, 2007.

Ilcol YO, Cansev M, Yilmaz MS, Hamurtekin E andUlus IH. Intraperitoneal administration of CDP-choline and its cholinergic and pyrimidinergicmetabolites induce hyperglycemia in rats:Involvement of the sympathoadrenal system.Archives of Physiology and Biochemistry113(4/5):186-201, 2007.

Ilcol YO, Cansev M, Yilmaz MS, Hamurtekin E andUlus IH. Peripheral administration of CDP-cholineand its cholinergic metabolites increases seruminsulin: Peripheral muscarinic and nicotinic acetyl-choline receptors are both involved in its action.Neuroscience Letters 431(1):71–76, 2008.

Cansev M, Ilcol YO, Yilmaz MS, Hamurtekin E andUlus IH. Peripheral administration of CDP-choline,phosphocholine or choline increases plasmaadrenaline and noradrenaline concentrations.Autonomic and Autacoid Pharmacology28:41–58, 2008.

GRANTS

Richard E. Dearborn Jr.

PROJECT: Mutagenic analysis of conserved aminoacid function in the tumor suppressor Vitamin D3Up-regulated Protein 1 (VDUP1)

SPONSOR: Albany College of PharmacyIntramural Grant

TOTAL GRANT: $5,000

PROJECT PERIOD: 2007–2008

Carlos Feleder

PROJECT: The role of the spleen in the febrileresponse

SPONSOR: National Institutes of Health


PROJECT PERIOD: October 2007–September2010

PROJECT: The spleen releases a splenic inhibitoryfactor that controls LPS fever

SPONSOR: American Association of Colleges ofPharmacy


PROJECT PERIOD: January 2007–December2010

PROJECT: Splenic regulation of endotoxic fever


TOTAL GRANT: $5,000


Arnold Johnson

PROJECT: Biomarkers predicting the severity ofobstruction-induced bladder dysfunction

SPONSOR: Merit Review Award, Dept. of VeteransAffairs

PRINCIPAL INVESTIGATOR: Robert M. Levin


PROJECT PERIOD: April 2006–March 2010

PROJECT: A mechanism for TNF inducedendothelial dysfunction

SPONSOR: National Institute of Health, NHLBI


PROJECT PERIOD: January 2005–January 2009

Robert M. Levin

PROJECT: Protection against ischemia andischemia followed by reperfusion by AntrodiaCamphorata

SPONSOR: Wellshine Pharmaceuticals



PROJECT: Biomarkers predicting the severity ofobstructive bladder dysfunction

SPONSOR: Veteran’s Administration MedicalCenter



Luciana Lopes

TITLE: Use of campul-based microemulsions astopical delivery systems

SPONSOR: Scholarship of Discovery Grant,Albany College of Pharmacy

TOTAL GRANT: $5,000

PROJECT PERIOD: May 2008–June 2009

Adwoa O. Nornoo

PROJECT: Detection of penicillin G in blisterpacks of various drugs packaged by Heartland,Inc.

SPONSOR: Office of the New York State AttorneyGeneral

TOTAL GRANT: $2,200

PROJECT PERIOD: October 2007–January 2008


PROJECT: Leptin is a pro-inflammatory cytokine:True or false?

SPONSOR: Scholarship of Discovery Grant,Albany College of Pharmacy

TOTAL GRANT: $4,500

PROJECT PERIOD: May 2008–June 2009

Jeffrey M. Voigt

PROJECT: Regulation of VDUP-1 expression inhuman tumor cells


TOTAL GRANT: $5,000

PROJECT PERIOD: July 2008–June 2009

PROJECT: Post-translational modification ofVDUP-1 in human cells


TOTAL GRANT: $5,000

PROJECT PERIOD: July 2007–June 2008

HaiAn Zheng

PROJECT: Computer 3D molecular modeling andanimation for pharmaceutics and pharmacyEducation

SPONSOR: Scholarship of Discovery andEducational Excellence, Albany College ofPharmacy

TOTAL GRANT: $5,000

PROJECT PERIOD: May 2008–May 2009


Richard E. Dearborn

Voigt JM, Basle J and Dearborn Jr. RE.Phosphorylation of VDUP-1 in human U-87 MGglioma cells. American Association for CancerResearch Annual Meeting, San Diego, Calif., April2008.

Mandalaywala NV, Chang S, Snyder RG,Levendusky MC and Dearborn Jr. RE. Retinalaxon-dependent regulation of vitamin D3 up-reg-ulated protein 1 (VDUP1) tumor suppressorexpression in the Drosophila optic lobe.Neurobiology of Drosophila meeting, Cold SpringHarbor, N.Y., October 2007.


Mandalaywala NV, Chang S, Snyder RG,Levendusky MC and Dearborn Jr. RE. Retinalaxon-dependent regulation of vitamin D3 up-reg-ulated protein 1 (VDUP1) tumor suppressorexpression in the Drosophila optic lobe.Commission on Independent Colleges andUniversities Undergraduate Research Exposition,Albany, N.Y., January 2008.

Carlos Feleder

Marlow J, Yilmaz MS, Millington WR and FelederC. Dose-dependent mechanisms mediatelipopolysaccharide hypotension in male rats.Experimental Biology, San Diego, Calif., April2008.

Yilmaz MS, Myer BS, Feleder C and MillingtonWR. Blockade of alpha-adrenergic receptors inthe preoptic anterior hypothalamus preventslipopolysaccharide evoked hypotension.Experimental Biology, San Diego, Calif., April2008.

Robert M. Levin

Levin RM. Update on studies on obstructive blad-der dysfunction. Lund University, Lund, Sweden,September 2007.

Levin RM. Ischemic etiology of obstructive blad-der dysfunction: Effect of Antrodia Camphorata.Antrodia Comphorata Symposium, Taipei, Taiwan,March 2008.

Levin RM. Ischemic etiologies of male and femaleurological dysfunctions. Veteran’s GeneralHospital, Taipei, Taiwan, March 2008.

Levin RM. Beneficial effects of AntrodiaComphorata. Taichung General Hospital, Taichung,Taiwan, March 2008.

Levin RM. Anti-ischemic effects of AntrodiaComphorata. Taipei General Hospital, Taipei,Taiwan, March 2008.

Luciana B. Lopes

Hosmer J, Reed R, Nornoo AO, Lopes LB.Influence of microemulsion composition on theskin penetration and percutaneous delivery ofProgesterone. 11th Annual American Associationof Pharmaceutical Scientists Northeast RegionalDiscussion Group, Rocky Hill, Conn., April 2008.

Komalavilas P, Lopes LB, Flynn CR, Smoke C, SealB, Panitch A and Brophy CM. Reduction of heatchock protein 27 phosphorylation inhibits thedevelopment of intimal hyperplasia. ExperimentalBiology 2008, San Diego, Calif., April 2008.

William R. Millington

Yilmaz MS, Myer BS, Feleder C and MillingtonWR. Blockade of α-adrenergic receptors in thepreoptic area/anterior hypothalamus preventslipopolysaccharide evoked hypotension.Experimental Biology 2008, San Diego, Calif.,April 2008.

Marlow J, Yilmaz MS, Millington WR and FelederC. Dose-dependent mechanisms mediatelipopolysaccharide (LPS) hypotension in malerats. Experimental Biology 2008, San Diego, Calif.,April 2008.

Adwoa O. Nornoo

Nornoo AO and Chikhale P. Microemulsion-basedformulations of Paclitaxel: Anticancer activityagainst rat glioma cells and intestinal permeability.2007 American Association of PharmaceuticalScientists Annual Meeting and Exposition, SanDiego, Calif., November 2007.

Nornoo AO and Zheng H. Pharmacokinetics andNMR characterization of Paclitaxel microemul-sions. 2007 American Association ofPharmaceutical Scientists Annual Meeting andExposition, San Diego, Calif., November 2007.


Romanovsky AA, Steiner AA, Turek VF, AlmeidaMC, Burmeister JJ, Oliveira DL, Roberts JL,Bannon AW, Norman MH, Louis J-C, Treanor JJSand Gavva NR. Non-thermal activation of TRPV1channels in abdominal viscera tonically inhibitsautonomic cold-defense effectors. 37th AnnualMeeting of the Society for Neuroscience, SanDiego, Calif., 2007.

Jeffrey M. Voigt

Basle J and Voigt JM. Phosphorylation of VDUP-1in human U87-MG glioma cells. AmericanAssociation for Cancer Research, San Diego.,Calif., April 2008.

M. Sertac Yilmaz

Yilmaz MS, Myer BS, Feleder C and MillingtonWR. Blockade of α-adrenergic receptors in thepreoptic area/anterior hypothalamus preventslipopolysaccharide evoked hypotension.Experimental Biology 2008, San Diego, Calif.,April 2008.

Marlow J, Yilmaz MS, Millington WR and FelederC. A neural route signals the brain in endotoxichypotension: Role of the vagus nerve and α-adrenoceptors in the preoptic anterior hypothala-mic area. Experimental Biology 2008, San Diego,Calif., April 2008.

HaiAn Zheng

Nornoo AO and Zheng H. Pharmacokinetics andNMR characterization of paclitaxol microemulsion.American Association of PharmaceuticalScientists Annual Meeting, San Diego, Calif.,November 2007.


ACPHS 2008 // 37

PUBLICATIONS

James Anderson

Anderson J and Applegate E. The psychologicalrobot: A new tool for learning. InternationalJournal of Teaching and Learning in HigherEducation 19(3):305-314, 2007.

Kenneth J. Blume

Blume KJ. The talented tenth and American for-eign policy: African-Americans in the U.S.Diplomatic Corps, 1865-1914. The Mind’s Eye: ALiberal Arts Journal (Massachusetts College ofLiberal Arts), 2007.

Blume KJ. Entries on Rush-Bagot Treaty, Anglo-American Treaty, Adams-Onis Treaty, Webster-Ashburton Treaty, Oregon Treaty, Treaty ofGuadalupe Hidalgo, Alaska Purchase, BurlingameTreaty, Hay-Herran Treaty and Hay-Bunau-VarillaTreaty in Encyclopedia of the Age of Imperialism:1800–1914 (Carl Cavanagh Hodge, ed.), Westport,Conn.:Greenwood Press, 2007.

Blume KJ. Entries on Alexander Clark, WilliamHenry Harrison Heard, William Frank Powell andJohn E. W. Thompson in African AmericanNational Biography (Henry Louis Gates andEvelyn Higginbottom, eds.), New York: OxfordUniversity Press, 2008.

Blume KJ. Review of Angus Curry’s The Officersof the CSS Shenandoah. H-Maritime, May 2007.

Blume KJ. Review of Eric J. Graham and ClydeBuilt’s Blockade Runners, Cruisers and ArmouredRams of the American Civil War. The NorthernMarine/Le Marin Du Nord, July 2007.

Margaret Lasch Carroll

Carroll ML. Prodigals’ dreams: John McGahern’sThat They May Face the Rising Sun. EstudiosIrlandeses 3:42-53, 2008.

Ray Chandrasekara

Chandrasekara R. Borders, boundaries, bodies:Caliban re-membered. International Journal ofthe Humanities 5(10):189-98, 2007.

Chandrasekara R and Polimeni JM. Water andnational security. International Journal ofInterdisciplinary Social Sciences 2(6):11-20, 2008.

Chandrasekara R. Entries on When the RainbowGoddess Wept and Ninotchka Rosca inEncyclopedia of American EthnicLiterature/Asian American volume (Seiwong Oh,ed.), Facts on File, 2008.

J. Daniel d’Oney

d’Oney JD. Watered by tempests: Hurricanes inthe cultural fabric of the United Houma Nation.American Indian Culture and Research Journal32(2):11-26, 2008.

d’Oney JD. River queens, sternwheelers andcanyon cats. Pacific Northwest Quarterly.99(1):40-42, Winter 2007/2008.

Martha A. Hass

Siflinger-Birnboim A, Levin RM and Hass MA.Partial outlet obstruction of the rabbit urinarybladder induces selective protein oxidation.Neurourology and Urodynamics 26:1-7, 2007.

Hass MA, Siflinger-Birnboim A and Levin RM.Hydroxynonenal in obstructed urinary bladderdisease. Federation of American Societies forExperimental Biology Journal 21(6):lb31, April2007.

Kevin M. Hickey

Hickey KM and Karatsolis A. A Rocky-Horror-Picture Show pedagogy: Tablet PC use inHumanities and Communication student-centeredclassrooms. University College of the FraserValley Research Review 1(3): 26-37.

Hickey KM. Entries on Exploration and Explorers,Africa; Ralph Ellison; Morant Bay Rebellion; Race,History of; and Soukous in Africa and theAmericas: Culture, Politics, and History (3 vol-umes, Richard M. Juang and Noelle Morrissette,eds.). Santa Barbara: ABC-CLIO Press, 2008.

Marion Jacobson

Jacobson M. Searching for rockordion: Thechanging image of the accordion in America inthe Twentieth Century. American Music 3: 123-159.

Andreas Karatsolis

Hickey KM and Karatsolis A. A Rocky-Horror-Picture Show pedagogy: Tablet PC use inHumanities and Communication student-centeredclassrooms. University College of the FraserValley Research Review 1(3): 26–37.

Karatsolis A. Revamping the honor code in a pro-fessional curriculum. Integrity Matters: Center forAcademic Integrity, 2008.

Karatsolis A. Tablets as writing canvases and con-struction sites in The Impact of Tablet PCs andPen-based Technology on Education: Vignettes,Evaluations, and Future Directions (Berque, et al,eds.), Purdue University Press, September 2007.

Michael Pittman

Pittman M. Soul making in all and everything.Proceedings of the 12th International HumanitiesConference: All and Everything InternationalHumanities Conference 2007.

Laura Rogers

Rogers L. Finding our way from within: Criticalpedagogy in a prison writing class. Open Words2(1): 22–48, Spring 2008.

Sandra Winn

Winn S. George Elder’s story “Passion andSparks.” The Authentic Dissertation: AlternativeWays of Knowing, Research and Representation(Four Arrows AKA Don Trent Jacobs). New York:Routledge Press. pp 175-184.


Patricia Baia

Baia P. CDETG: Active learning: In or outside theclassroom. Albany College of Pharmacy, Albany,N.Y., June 2008.

Kenneth J. Blume

Blume KJ. Who needs to know about theSchlieffen Plan? Focusing on the ’big picture’ andWorld War I. World History Association AnnualConference, University of Wisconsin, Milwaukee,Wisc. July 2007.

Margaret Carroll

Carroll M. Conflict, coexistence and community:Creatures of the Earth by John McGahern.American Conference of Irish Studies NationalConference, St. Ambrose University, Davenport,Iowa, April 2008.

Ray Chandrasekara

Chandrasekara R. Borders, boundaries, bodies:Caliban re-membered. International HumanitiesConference, Paris, France, July 2007.

Chandrasekara R. Water and state security.International Social Science Conference, Grenada,Spain, July 2007.

J. Daniel d’Oney

D’Oney JD. Have You Heard: The Past in FirstPerson from the T. Harry Williams Center for OralHistory (researched and curated the section onthe United Houma Nation for museum exhibit).Hill Memorial Library, Baton Rouge, October 22,2007–March 30, 2008.

Ellen B. Duffy

Duffy EB and Harton JA. Anthrax lethal toxinsinduces caspase-independent apoptosis in humanand murine macrophage cell lines. AmericanSociety for Microbiology 108th General Meeting,Boston, Mass., June 2008.

Martha A. Hass

Hass MA, Siflinger-Birnboim A and Levin RM.Hydroxynonenal in obstructed urinary bladderdisease. Federation of American Societies forExperimental Biology/ Annual ExperimentalBiology meeting, Washington, D.C., April 2007.

Kevin M. Hickey

Hickey KM. Diverting “les flots souterrains” to cul-tivate the cosmopolitans in Veronique Tadjo’sL’Ombre d’Imana (The Shadow of Imana). 34thAnnual Conference of the African LiteratureAssociation, Macomb, Ill., April 2008.

Marion Jacobson

Jacobson M. Italian dance hall culture: The accor-dion as a symbol of pluralism and ethnicity.Italians in the Americas Conference, New York,N.Y., April 2008.

Andreas Karatsolis

Karatsolis A. Designing effective websites:Innovation in project-based learning. AmericanAssociation of Colleges of Pharmacy AnnualMeeting, Orlando, Fla., July 2007.

Arts and Sciences


Erika A. Muse

Muse EA. From theory to practice: Building com-petencies in intercultural encounters in AsianAmerica. Association for Asian American Studies,Chicago, Ill., April 2008.

Michael Pittman

Pittman M. Gurdjieff: Religion and its discontents.American Society for Esoteric Studies Conferencein Charleston, S.C., May-June, 2008.

Pittman M. Gurdjieff’s view of education in All andEverything. Armenia-Gurdjieff Conference,Yerevan, Armenia, July 2007.

Laura Rogers

Rogers L. Diving Into prison teaching: MinaShaughessy, teacher development and the reali-ties of prison teaching. Conference on CollegeComposition and Communication, New Orleans,La., April 2008.

Elisabeth A. Vines

Vines E. Pictures of potatory pleasures:Nineteenth century France. Fourth InternationalConference on Drugs and Alcohol in History,Guelph, Ontario, Canada, August 2008.

Sandra Winn

Winn S. Our strategy for achieving toleranceamong our campus community. NationalAssociation for Multicultural Education meeting,Baltimore, Md., October-November 2007.

Winn S. Implications for moral education practicesfrom the field. Association for Moral Education,New York, N.Y., November 2007.

EXHIBITIONS

Elisabeth E. Vines

Vines EA. Oil works (21 recent paintings).Bethlehem Public Library, Delmar, N.Y., January2008.

Vines EA. New Mustache. Third Annual Members’Show, Albany Center Gallery, Albany, N.Y.,December 2007–January 2008.

Vines EA. Window Series (11 oil paintings). Café atthe Honest Weight Food Co-op, Albany, N.Y.,September 2007.

GRANTS

Kenneth J. Blume

PROJECT: Sable Diplomats: African Americans inthe U.S. Diplomatic Corps, 1865-1914

SPONSOR: Albany College of Pharmacy

TOTAL GRANT: $3,240


Martha Hass

PROJECT: Ischemic etiology of obstructive blad-der dysfunction

SPONSOR: National Institutes of Health—NationalInstitute of Diabetes, Digestive and KidneyDisease

PRINCIPAL INVESTIGATOR: Robert Levin

TOTAL GRANT: $1,154,280

PROJECT PERIOD: 2004–2008.

PROJECT: The role of the spleen in the febrileresponse

SPONSOR: National Institutes of Health—Neuroendocrinology, Neuroimmunology andBehavior

PRINCIPAL INVESTIGATOR: Carlos Feleder


PROJECT PERIOD: 2008–2010.

Michael Pittman

PROJECT: Armenia-Gurdjieff Conference (organ-izer)

SPONSOR: Indications Press

TOTAL GRANT: $600

PROJECT PERIOD: July 2007

Health Sciences


Indra Balachandran

Balachandran I and Walker J. Curriculum map-ping. 55th Annual Meeting of the AmericanSociety of Cytopathology, Houston, Tex.,November 2007.

Balachandran I. Small blue cell tumors of child-hood: Case study approach. TeleconferenceNetwork of Texas series, University of TexasHealth Science Center, San Antonio, Tex., March2008.

Bolded names indicate ACPHS faculty collaborators


ACPHS 2008 // 39

BSPS STUDENTS

PUBLICATIONS

Juan Y-S, Mannikarottu A, Hydery T, Lin W-Y,Kogan BA, Whitbeck C, Leggett RE, Levin RM.Coenzyme Q10 protect against ischemia / reper-fusion induced biochemical and functionalchanges in rabbit urinary bladder. Molecular andCellular Biochemistry 311:73-80, 2008.

Juan Y-S, Levin RM, Hydery T, Chuang SM, Li S,Leggett RE, Huang CH, Mannikarottu A.Protective effect of coenzyme Q10 plus lipoic acidagainst obstructive bladder dysfunctions in therabbit. Journal of Urology (In Press).

Lin W-Y, Rehfuss A, Whitbeck C, Juan W-S,Chichester, Mannikarottu A, Levin RM. Effect ofLetrozole on female rabbit Urinary bladder func-tion. BJU International 100:1391-1395, 2007.

Lin W-Y, Rehfuss A, Whitbeck C, Levin RM. Effectof coenzyme Q10 and α-lipoic acid on theresponse of the rabbit urinary bladder to repeti-tive stimulation and in vitro ischemia. Urology72(1):214-9, July 2008 [Epub, February 2008].

Lin W-Y, Radu F, Schuler C, Leggett RE,Mannikarottu A, Levin RM. Effect of ovariectomyand estrogen therapy on the free fatty acid con-tent, endogenous lipase activity, and phospholipidcontent of the rabbit urinary bladder. BJUInternational 102(7):885-9, September 2008[EPub, May 2008]

Mandalaywala NV, Chang S, Snyder RG,Levendusky MC, Voigt JM, Dearborn Jr RE. Thetumor suppressor, vitamin D3 up-regulated pro-tein 1 (VDUP1), functions downstream of REPOduring Drosophila gliogenesis. DevelopmentalBiology 315:489-504, 2008.

Yilmaz, MS, Göktalay G, Myer BS, Millington WR,Cutrera R, Feleder C. Lipopolysaccharide-inducedhypotension is mediated by a neural pathwayinvolving the vagus nerve, the nucleus tractussolitarius and alpha-adrenergic receptor in thepreoptic anterior hypothalamic area. Journal ofNeuroimmunology 203(1):39-49, October 2008.

ABSTRACTS

Juan Y-S, Mannikarottu A, Hydery T, Kogan BA,Schuler C, Leggett RE, Levin RM, Coenzyme Q10and alpha lipoic acid as a treatment for partialbladder outlet obstruction induced bladder dys-function. American Urological Society Meeting,Orlando, Fla., May 2008.

Radu F, Lin W-Y, Chichester P, Leggett RE,Mannikarottu A, Levin RM. Effect of ovariectomyand estrogen administration on free fatty acid,and phospholipid concentrations of the rabbit uri-nary bladder muscle and mucosa. AmericanUrological Society Meeting, Orlando, Fla., May2008.

Nornoo AO, Owusu-Obeng A, Myer BS, NguyenH, Reed R. Effect of oral microemulsions (MEs) onthe permeability (peff) of paclitaxel (PAC) acrossrat GIT and caco-2 cell monolayers. AmericanAssociation for Cancer Research Annual Meeting,Los Angeles, Calif., April 2007.

Mandalaywala NV, Chang S, Snyder RG,Levendusky MC, Dearborn Jr, RE. Retinal axon-dependent regulation of vitamin D3 up-regulatedprotein 1 (VDUP1) tumor suppressor expression inthe Drosophila optic lobe. Cold Spring HarborNeurobiology of Drosophila Meeting, Cold SpringHarbor, NY, October 2007.

Mandalaywala NV, Chang S, Snyder RG,Levendusky MC, Dearborn Jr, RE. Retinal axon-dependent regulation of vitamin D3 up-regulatedprotein 1 (VDUP1) tumor suppressor expression inthe Drosophila optic lobe. CICU UndergraduateResearch Exposition, Albany, NY, January 2008.

Voigt JM, Basle J, Dearborn Jr, RE.Phosphorylation of VDUP-1 in human U-87 MGglioma cells. AACR Annual Meeting, San Diego,Calif., April 2008.

Marlow J, Yilmaz MS, Millington W, Feleder C.Dose-dependent mechanisms mediatelipopolysaccharide hypotension in male rats.Experimental Biology 2008, San Diego, Calif.,April 2008.

Yilmaz MS, Myer BS, Feleder C, Millington W.Blockade of alpha-adrenergic receptors in thepreoptic anterior hypothalamus preventslipopolysaccharide evoked hypotension.Experimental Biology 2008, San Diego, Calif.,April 2008.

PHARM.D. STUDENTS

PUBLICATIONS

Mandalaywala NV, Chang S, Snyder RG,Levendusky MC, Voigt JM, Dearborn Jr RE. Thetumor suppressor, vitamin D3 up-regulated protein1 (VDUP1), functions downstream of REPO duringDrosophila gliogenesis. Developmental Biology315:489-504, 2008.

Nornoo A, Zheng H, Lopes LB, Reed R, et al. Oral microemulsions of paclitaxel in situ andphamacokinetic studies. European Journal of Pharmaceutics and Biopharmaceutics71(2):310–7, February 2009.

ABSTRACTS

Wong P, Blustein L, Policastro C, Zheng H.Pharmaceutics Online-Homework: CalculationPractice and Evaluation in Large-Class. AACPAnnual Conference, 2008.

Hosmer J, Reed R, Nornoo N, Lopes LB. Influenceof microemulsion composition on the skin pene-tration and percutaneous delivery of proges-terone. 11th Annual AAPS Northeast RegionalDiscussion Group, Rocky Hill, Conn., April 2008.

Nornoo AO, Owusu-Obeng A, Myer BS, NguyenH, Reed R. Effect of oral microemulsions (MEs) onthe permeability (peff) of paclitaxel (PAC) acrossrat GIT and caco-2 cell monolayers. AmericanAssociation for Cancer Research Annual Meeting,Los Angeles, Calif., April 2007.

Mandalaywala NV, Chang S, Snyder RG,Levendusky MC, Dearborn Jr, RE. Retinal axon-dependent regulation of vitamin D3 up-regulatedprotein 1 (VDUP1) tumor suppressor expression inthe Drosophila optic lobe. Cold Spring HarborNeurobiology of Drosophila Meeting, Cold SpringHarbor, NY, October 2007.

Mandalaywala NV, Chang S, Snyder RG,Levendusky MC, Dearborn Jr, RE. Retinal axon-dependent regulation of vitamin D3 up-regulatedprotein 1 (VDUP1) tumor suppressor expression inthe Drosophila optic lobe. CICU UndergraduateResearch Exposition, Albany, NY, January 2008.

Department of Pharmaceutical Sciences—Student Publications

Bolded names indicate ACPHS students


Go green and make your gift online www.acphs.edu, click on Online Giving.ACPHS accepts both MasterCard and Visa

Telephone 518.694.7253

Toll Free 888.203.8010

Please make checks payable to Albany College of Pharmacy and Health Sciences and mail to

Office of Institutional Advancement

Albany College of Pharmacy and Health Sciences

106 New Scotland Ave.

Albany, New York 12208

ENABLE STUDENT

AND FACULTY RESEARCH

ENSURE STATE-OF-THE-ART

RESEARCH LABS AND

PROGRESSIVE TECHNOLOGIES

SUPPORT STUDENT

SCHOLARSHIP AND

FACULTY DEVELOPMENT

AcademicExcellence +ResearchOpportunities

Make a difference to the ACPHS community.

The possibilities are endless with your gift.


OFFICERS

Kandyce J. Daley ’74 CHAIR

Hugh A. Johnson VICE CHAIR

Christopher Del Vecchio ’88 TREASURER

Bridget-ann Hart ’80 SECRETARY

TERM TRUSTEES

Stephen C. AinlayJames E. Bollinger ’58Robert S. BuschHerbert ChorbajianJ. Gordon Dailey ’57Richard H. Daffner ’63Francis J. DiLascia ’54Melvin Friedland ’58Geno J. Germano Jr. ’83Zachary I. Hanan ’63David M. Kile ’74Jeannette S. Lamb ’57Joseph LapetinaThomas O. MaggsRobert F. McGaugh ’57Christopher MitiguyFouad MorkosRichard G. Robison ’52

CHAIRMAN EMERITUS

Alfred J. Collins Jr. ’53

TRUSTEES EMERITUS

Michael BetteKenneth M. Nirenberg

OFFICE OF GRANTS ADMINISTRATION

Sunita ChowfinGRANTS ADMINISTRATOR

[email protected]

PHARMACEUTICAL RESEARCH INSTITUTE

Shaker A. Mousa, Ph.D.EXECUTIVE VICE PRESIDENT AND CHAIRMAN

[email protected]

Vicki A. DiLorenzoVICE PRESIDENT OF INSTITUTIONAL ADVANCEMENT

[email protected]

David ZdunczykASSISTANT VICE PRESIDENT OF INSTITUTIONAL ADVANCEMENT

[email protected]

Donna BeebeDIRECTOR OF MAJOR GIFTS

[email protected]

Michael J. BuckleyMAJOR GIFTS OFFICER

[email protected]

Gil ChorbajianEXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS

[email protected]

Deanna Ennello-ButlerDIRECTOR OF ADVANCEMENT RESEARCH

[email protected]

Candace MaddenSYSTEMS ADMINISTRATOR

[email protected]

Patrick RathbunASSISTANT DIRECTOR OF MARKETING AND COMMUNICATIONS

[email protected]

Deborah S. ReutterCOORDINATOR OF INSTITUTIONAL ADVANCEMENT

[email protected]

Christine A. ShieldsDIRECTOR OF COLLEGE PUBLICATIONS

[email protected]

Christina Spinelli SanvidgeCOORDINATOR OF DONOR RELATIONS AND STEWARDSHIP

COORDINATOR OF ACPHS ACADEMY

[email protected]

James J. Gozzo, Ph.D.PRESIDENT

Mehdi Boroujerdi, Ph.D., Pharm.D.DEAN

A L B A N Y C O L L E G E O F P H A R M AC Y A N D H E A LT H S C I E N C E S

Office of Institutional Advancement

Research

Board of Trustees


NON-PROFIT ORG

US POSTAGE

PaidALBANY NY

PERMIT NO. 349


president's report 2008

Documents

pm page

placeat acphs

student h ighl ights

faculty h ighl ights

global importance

anactive grant

health care

years report